{ "data": { "id": "org_clinicaltrials-gov", "slug": "clinicaltrials-gov", "name": "ClinicalTrials.gov (U.S. National Library of Medicine)", "short_name": "ClinicalTrials.gov", "type": "government", "tier": 1, "homepage": "https://clinicaltrials.gov", "country_code": "US", "reliability_note": "Registry of record for clinical studies, run by the U.S. National Library of Medicine. Counts are live query results: sponsors register, update and correct records continuously, and studies registered only in other registries are absent.", "url": "https://statorigin.org/sources/clinicaltrials-gov", "documents": [ { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Inclisiran (PCSK9 siRNA) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Anti-amyloid antibodies (all) (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=lecanemab%20OR%20donanemab%20OR%20aducanumab%20OR%20gantenerumab%20OR%20solanezumab%20OR%20trontinemab%20OR%20remternetug%20OR%20BAN2401&query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Base editing (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Mazdutide (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=mazdutide%20OR%20IBI362&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Cadonilimab (PD-1 x CTLA-4) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=cadonilimab%20OR%20AK104&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of T-cell engagers (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab%20OR%20%22T%20cell%20engager%22&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Amivantamab (EGFR x MET) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=amivantamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Datopotamab deruxtecan (TROP2) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in vasculitis, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=vasculitis&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist or a GLP-1-based multi-agonist (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, mazdutide, MariTide, amycretin and others, including development codes) in heart failure or cardiovascular disease, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&query.cond=%22heart%20failure%22%20OR%20cardiovascular%20OR%20atherosclerosis&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Trontinemab (brain shuttle) (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=trontinemab%20OR%20RO7126209&query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist or a GLP-1-based multi-agonist (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, mazdutide, MariTide, amycretin and others, including development codes) in mash / nash, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&query.cond=NASH%20OR%20MASH%20OR%20steatohepatitis&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Cadonilimab (PD-1 x CTLA-4) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=cadonilimab%20OR%20AK104&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist or a GLP-1-based multi-agonist (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, mazdutide, MariTide, amycretin and others, including development codes) in alcohol or substance use, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&query.cond=alcohol%20OR%20%22substance%20use%22%20OR%20addiction%20OR%20smoking%20OR%20opioid&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in colorectal cancer, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&query.cond=colorectal%20OR%20colon%20OR%20rectal&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in inherited eye disease, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&query.cond=retinal%20OR%20Leber%20OR%20retinitis&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic lupus erythematosus / lupus nephritis, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of IL-23 p19 antibodies (within: interventional drug or biologic studies in ulcerative colitis or Crohn's disease) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=guselkumab%20OR%20mirikizumab%20OR%20risankizumab%20OR%20tildrakizumab&query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of S1P modulators (within: interventional drug or biologic studies in ulcerative colitis or Crohn's disease) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=etrasimod%20OR%20ozanimod&query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in inherited liver and metabolic disease, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&query.cond=amyloidosis%20OR%20angioedema%20OR%20hypercholesterolemia%20OR%20%22alpha-1%20antitrypsin%22%20OR%20%22ornithine%20transcarbamylase%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in mash / nash, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&query.cond=NASH%20OR%20MASH%20OR%20steatohepatitis&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of In vivo liver editing (LNP) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=NTLA-2001%20OR%20nexiguran%20OR%20NTLA-2002%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20CTX310%20OR%20CTX320%20OR%20BEAM-302%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in gastric, oesophageal or colorectal cancer, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=gastric%20OR%20esophageal%20OR%20colorectal&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of JAK inhibitors (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=upadacitinib%20OR%20tofacitinib%20OR%20filgotinib%20OR%20ritlecitinib%20OR%20ivarmacitinib&query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Agitation and psychosis in Alzheimer's (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=brexpiprazole%20OR%20AXS-05%20OR%20pimavanserin%20OR%20xanomeline%20OR%20masupirdine%20OR%20dextromethorphan&query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in urothelial or bladder cancer, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=urothelial%20OR%20%22bladder%20cancer%22%20OR%20%22bladder%20carcinoma%22%20OR%20%22bladder%20neoplasm%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Anti-integrin (vedolizumab and others) (within: interventional drug or biologic studies in ulcerative colitis or Crohn's disease) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=vedolizumab%20OR%20etrolizumab%20OR%20ontamalimab%20OR%20MORF-057&query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in vasculitis, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=vasculitis&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of PSMA-targeted (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=PSMA%20AND%20%28Lutetium%20OR%20177Lu%20OR%20Actinium%20OR%20225Ac%20OR%20212Pb%29&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Retatrutide (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=retatrutide%20OR%20LY3437943&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in sickle cell disease or beta-thalassaemia, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&query.cond=sickle%20OR%20thalassemia&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Mazdutide (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=mazdutide%20OR%20IBI362&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of S1P modulators (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=etrasimod%20OR%20ozanimod&query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Oral PCSK9 inhibitors (enlicitide, AZD0780) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=enlicitide%20OR%20MK-0616%20OR%20AZD0780&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of SHR-A1811 / trastuzumab rezetecan (HER2) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Lecanemab (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=lecanemab%20OR%20BAN2401&query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-27, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Sacituzumab tirumotecan (TROP2) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in lung cancer, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&query.cond=%22lung%20cancer%22%20OR%20NSCLC%20OR%20SCLC&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Trontinemab (brain shuttle) (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=trontinemab%20OR%20RO7126209&query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in kidney cancer, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&query.cond=%22renal%20cell%22%20OR%20%22kidney%20cancer%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic lupus erythematosus / lupus nephritis, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Sotorasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=sotorasib%20OR%20%22AMG%20510%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: All interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product, any start date, as registered on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Sacituzumab tirumotecan (TROP2) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of BCMA-directed (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%28%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%29%20AND%20BCMA&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in lymphoma, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=lymphoma&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in pancreatic cancer, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&query.cond=pancreatic&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in liver or biliary cancer, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=hepatocellular%20OR%20%22liver%20cancer%22%20OR%20biliary%20OR%20cholangiocarcinoma&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: All interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents), any start date, as registered on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Retatrutide (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=retatrutide%20OR%20LY3437943&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lung cancer, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&query.cond=%22lung%20cancer%22%20OR%20NSCLC%20OR%20SCLC&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Lutetium-177 agents (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: All interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others), any start date, as registered on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of BL-B01D1 (EGFR x HER3 bispecific ADC) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=BL-B01D1%20OR%20izalontamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of JAK inhibitors (within: interventional drug or biologic studies in ulcerative colitis or Crohn's disease) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=upadacitinib%20OR%20tofacitinib%20OR%20filgotinib%20OR%20ritlecitinib%20OR%20ivarmacitinib&query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CD20 x CD3 T-cell engagers (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20odronextamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Ivonescimab (PD-1 x VEGF) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=ivonescimab%20OR%20AK112%20OR%20SMT112&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in neuroendocrine tumours, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&query.cond=neuroendocrine%20OR%20carcinoid%20OR%20paraganglioma%20OR%20pheochromocytoma&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: All interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy, any start date, as registered on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in type 2 diabetes, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&query.cond=%22type%202%20diabetes%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of MariTide (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=MariTide%20OR%20maridebart%20OR%20%22AMG%20133%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Amycretin (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=amycretin%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Disitamab vedotin (HER2) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22disitamab%20vedotin%22%20OR%20RC48&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-27, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Garsorasib, fulzerasib and glecirasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=garsorasib%20OR%20D-1553%20OR%20fulzerasib%20OR%20GFH925%20OR%20IBI351%20OR%20glecirasib%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-NK (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=CAR-NK%20OR%20%22NK%20cell%22&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Semaglutide (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Oral IL-23 receptor peptide (icotrokinra) (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=icotrokinra%20OR%20JNJ-77242113%20OR%20JNJ-2113&query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Donanemab (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=donanemab%20OR%20LY3002813&query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in multiple sclerosis, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=%22multiple%20sclerosis%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Base editing (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-26, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Lecanemab (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=lecanemab%20OR%20BAN2401&query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in obesity or overweight, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&query.cond=obesity%20OR%20overweight&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist or a GLP-1-based multi-agonist (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lymphoma, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&query.cond=lymphoma&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: All interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others), any start date, as registered on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in gastric or oesophageal cancer, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=gastric%20OR%20stomach%20OR%20esophageal%20OR%20gastroesophageal&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Semaglutide (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Tarlatamab (DLL3 x CD3) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=tarlatamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Amycretin (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=amycretin%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in inherited liver and metabolic disease, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&query.cond=amyloidosis%20OR%20angioedema%20OR%20hypercholesterolemia%20OR%20%22alpha-1%20antitrypsin%22%20OR%20%22ornithine%20transcarbamylase%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Sacituzumab govitecan (TROP2) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22sacituzumab%20govitecan%22%20OR%20IMMU-132&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic sclerosis, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=%22systemic%20sclerosis%22%20OR%20scleroderma&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in lung cancer, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&query.cond=%22lung%20cancer%22%20OR%20NSCLC%20OR%20SCLC&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Tirzepatide (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=tirzepatide%20OR%20LY3298176&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lymphoma, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=lymphoma&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CD20 x CD3 T-cell engagers (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20odronextamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in breast cancer, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=%22breast%20cancer%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in gastric, oesophageal or colorectal cancer, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=gastric%20OR%20esophageal%20OR%20colorectal&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-26, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of PD-(L)1 x VEGF bispecifics (all) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=ivonescimab%20OR%20AK112%20OR%20SMT112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20PF-08634404&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Olomorasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=olomorasib%20OR%20LY3537982&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Inclisiran (PCSK9 siRNA) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Lead-212 agents (alpha) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=212Pb%20OR%20Pb-212%20OR%20%22lead-212%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in neuroendocrine tumours, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&query.cond=neuroendocrine%20OR%20carcinoid%20OR%20paraganglioma%20OR%20pheochromocytoma&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of In vivo liver editing (LNP) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=NTLA-2001%20OR%20nexiguran%20OR%20NTLA-2002%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20CTX310%20OR%20CTX320%20OR%20BEAM-302%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in cancer, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Tarlatamab (DLL3 x CD3) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=tarlatamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis or Crohn's disease in crohn's disease, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Tirzepatide (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=tirzepatide%20OR%20LY3298176&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Gene-edited CAR-T or TCR-T (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%28CRISPR%20OR%20TALEN%20OR%20%22gene%20editing%22%20OR%20%22gene-edited%22%20OR%20%22base%20edited%22%29%20AND%20%28CAR%20OR%20TCR%20OR%20%22T%20cell%22%29&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of KRAS G12D-directed agents (inhibitors, degraders, vaccines, cell therapies) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=G12D%20OR%20MRTX1133%20OR%20HRS-4642%20OR%20INCB161734%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of TTR silencers (vutrisiran, patisiran, eplontersen, nucresiran) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in ovarian, cervical or endometrial cancer, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&query.cond=ovarian%20OR%20cervical%20OR%20endometrial&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: All interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others), any start date, as registered on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-26, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-26, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Daraxonrasib (pan-RAS) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=daraxonrasib%20OR%20RMC-6236&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist or a GLP-1-based multi-agonist (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-26, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in non-small cell lung cancer, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&query.cond=%22non-small%20cell%20lung%22%20OR%20NSCLC&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: All interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes), any start date, as registered on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in gastric or oesophageal cancer, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&query.cond=gastric%20OR%20stomach%20OR%20esophageal%20OR%20gastroesophageal&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Lead-212 agents (alpha) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=212Pb%20OR%20Pb-212%20OR%20%22lead-212%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist or a GLP-1-based multi-agonist (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, mazdutide, MariTide, amycretin and others, including development codes) in chronic kidney disease, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&query.cond=%22chronic%20kidney%20disease%22%20OR%20%22diabetic%20kidney%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Sacituzumab govitecan (TROP2) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22sacituzumab%20govitecan%22%20OR%20IMMU-132&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of GLP-1 receptor agonists (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20liraglutide%20OR%20exenatide%20OR%20tirzepatide&query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Tau-targeted therapies (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=BIIB080%20OR%20E2814%20OR%20bepranemab%20OR%20posdinemab%20OR%20semorinemab%20OR%20%22anti-tau%22%20OR%20%22tau%20antisense%22%20OR%20MAPT&query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Allogeneic or universal (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=allogeneic%20OR%20universal%20OR%20off-the-shelf&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Enfortumab vedotin (Nectin-4) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22enfortumab%20vedotin%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Datopotamab deruxtecan (TROP2) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Sotorasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=sotorasib%20OR%20%22AMG%20510%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Orforglipron (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=orforglipron%20OR%20LY3502970&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Ex vivo edited stem cells (sickle cell, thalassaemia) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%28CRISPR%20OR%20%22gene%20editing%22%20OR%20%22base%20editing%22%20OR%20exagamglogene%20OR%20CTX001%20OR%20BEAM-101%20OR%20reni-cel%20OR%20EDIT-301%29%20AND%20%28sickle%20OR%20thalassemia%29&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of GLP-1 receptor agonists (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20liraglutide%20OR%20exenatide%20OR%20tirzepatide&query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of TTR silencers (vutrisiran, patisiran, eplontersen, nucresiran) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: All interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others), any start date, as registered on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Orforglipron (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=orforglipron%20OR%20LY3502970&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Daraxonrasib (pan-RAS) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=daraxonrasib%20OR%20RMC-6236&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in liver or biliary cancer, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=hepatocellular%20OR%20%22liver%20cancer%22%20OR%20biliary%20OR%20cholangiocarcinoma&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lung cancer, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=%22lung%20cancer%22%20OR%20NSCLC%20OR%20SCLC&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Lp(a) lowering (olpasiran, lepodisiran, zerlasiran, pelacarsen, muvalaplin) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20SLN360%20OR%20pelacarsen%20OR%20TQJ230%20OR%20muvalaplin&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Donanemab (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=donanemab%20OR%20LY3002813&query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: All interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified, any start date, as registered on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Obefazimod (within: interventional drug or biologic studies in ulcerative colitis or Crohn's disease) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=obefazimod%20OR%20ABX464&query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of KRAS G12D-directed agents (inhibitors, degraders, vaccines, cell therapies) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=G12D%20OR%20MRTX1133%20OR%20HRS-4642%20OR%20INCB161734%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Trastuzumab deruxtecan (HER2) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Enfortumab vedotin (Nectin-4) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22enfortumab%20vedotin%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in sickle cell disease or beta-thalassaemia, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&query.cond=sickle%20OR%20thalassemia&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of BCMA-directed (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=BCMA&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Garsorasib, fulzerasib and glecirasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=garsorasib%20OR%20D-1553%20OR%20fulzerasib%20OR%20GFH925%20OR%20IBI351%20OR%20glecirasib%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: All interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease, any start date, as registered on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Tau-targeted therapies (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=BIIB080%20OR%20E2814%20OR%20bepranemab%20OR%20posdinemab%20OR%20semorinemab%20OR%20%22anti-tau%22%20OR%20%22tau%20antisense%22%20OR%20MAPT&query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in inherited eye disease, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&query.cond=retinal%20OR%20Leber%20OR%20retinitis&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Disitamab vedotin (HER2) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22disitamab%20vedotin%22%20OR%20RC48&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: All interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease, any start date, as registered on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in non-small cell lung cancer, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&query.cond=%22non-small%20cell%20lung%22%20OR%20NSCLC&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-NK (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=CAR-NK%20OR%20%22CAR%20NK%22%20OR%20%22CAR-NK%20cell%22%20OR%20%28%22chimeric%20antigen%20receptor%22%20AND%20%22NK%20cell%22%29&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Ex vivo edited stem cells (sickle cell, thalassaemia) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%28CRISPR%20OR%20%22gene%20editing%22%20OR%20%22base%20editing%22%20OR%20exagamglogene%20OR%20CTX001%20OR%20BEAM-101%20OR%20reni-cel%20OR%20EDIT-301%29%20AND%20%28sickle%20OR%20thalassemia%29&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in advanced solid tumours (basket), with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&query.cond=%22solid%20tumor%22%20OR%20%22solid%20tumors%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in myasthenia gravis, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=myasthenia&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified in ulcerative colitis, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-26, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Anti-integrin (vedolizumab and others) (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=vedolizumab%20OR%20etrolizumab%20OR%20ontamalimab%20OR%20MORF-057&query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: All interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents), any start date, as registered on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Allogeneic or universal (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%28%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%29%20AND%20%28allogeneic%20OR%20universal%20OR%20off-the-shelf%29&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in lung cancer, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=%22lung%20cancer%22%20OR%20NSCLC%20OR%20SCLC&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Adagrasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=adagrasib%20OR%20MRTX849&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Oral IL-23 receptor peptide (icotrokinra) (within: interventional drug or biologic studies in ulcerative colitis or Crohn's disease) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=icotrokinra%20OR%20JNJ-77242113%20OR%20JNJ-2113&query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in breast cancer, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&query.cond=%22breast%20cancer%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in multiple sclerosis, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=%22multiple%20sclerosis%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in chronic kidney disease, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&query.cond=%22chronic%20kidney%20disease%22%20OR%20%22diabetic%20kidney%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CagriSema / cagrilintide (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=cagrilintide%20OR%20CagriSema&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Trastuzumab deruxtecan (HER2) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Somatostatin-receptor-targeted (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%28DOTATATE%20OR%20DOTATOC%20OR%20edotreotide%20OR%20oxodotreotide%29%20AND%20%28Lutetium%20OR%20177Lu%20OR%20Actinium%20OR%20225Ac%20OR%20212Pb%29&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Pumitamig / BNT327 (PD-L1 x VEGF) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=pumitamig%20OR%20BNT327%20OR%20PM8002&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in myasthenia gravis, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=myasthenia&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of MariTide (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=MariTide%20OR%20maridebart%20OR%20%22AMG%20133%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Amivantamab (EGFR x MET) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=amivantamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-26, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: All interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer, any start date, as registered on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in lung cancer, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=%22lung%20cancer%22%20OR%20NSCLC%20OR%20SCLC&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of APOC3 (olezarsen, plozasiran) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=olezarsen%20OR%20plozasiran%20OR%20ARO-APOC3%20OR%20volanesorsen&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified in crohn's disease, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in ovarian, cervical or endometrial cancer, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=ovarian%20OR%20cervical%20OR%20endometrial&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CD19-directed (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%28%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%29%20AND%20CD19&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in alcohol or substance use, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&query.cond=alcohol%20OR%20%22substance%20use%22%20OR%20addiction%20OR%20smoking%20OR%20opioid&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in urothelial or bladder cancer, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&query.cond=urothelial%20OR%20bladder&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2026-09-27, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of ANGPTL3 (zodasiran, solbinsiran) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=zodasiran%20OR%20ARO-ANG3%20OR%20solbinsiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Anti-amyloid antibodies (all) (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=lecanemab%20OR%20donanemab%20OR%20aducanumab%20OR%20gantenerumab%20OR%20solanezumab%20OR%20trontinemab%20OR%20remternetug%20OR%20BAN2401&query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Obefazimod (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=obefazimod%20OR%20ABX464&query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Radium-223 (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CD19-directed (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=CD19&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in immune thrombocytopenia or autoimmune haemolytic anaemia, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=%22immune%20thrombocytopenia%22%20OR%20%22autoimmune%20hemolytic%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: All interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy, any start date, as registered on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Ivonescimab (PD-1 x VEGF) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=ivonescimab%20OR%20AK112%20OR%20SMT112&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in advanced solid tumours (basket), with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&query.cond=%22solid%20tumor%22%20OR%20%22solid%20tumors%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-26, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: All interventional drug or biologic studies in Alzheimer's disease, any start date, as registered on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in kidney cancer, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&query.cond=%22renal%20cell%22%20OR%20%22kidney%20cancer%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of APOC3 (olezarsen, plozasiran) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=olezarsen%20OR%20plozasiran%20OR%20ARO-APOC3%20OR%20volanesorsen&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in multiple myeloma, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=myeloma&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Somatostatin-receptor-targeted (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%28DOTATATE%20OR%20DOTATOC%20OR%20edotreotide%20OR%20oxodotreotide%29%20AND%20%28Lutetium%20OR%20177Lu%20OR%20Actinium%20OR%20225Ac%20OR%20212Pb%29&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in breast cancer, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=%22breast%20cancer%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Anti-TL1A antibodies (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=tulisokibart%20OR%20MK-7240%20OR%20PRA023%20OR%20duvakitug%20OR%20TEV-48574%20OR%20afimkibart%20OR%20RVT-3101%20OR%20RO7790121%20OR%20TL1A&query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Divarasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=divarasib%20OR%20GDC-6036&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist or a GLP-1-based multi-agonist (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, mazdutide, MariTide, amycretin and others, including development codes) in type 2 diabetes, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&query.cond=%22type%202%20diabetes%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Gene-edited CAR-T or TCR-T (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%28CRISPR%20OR%20TALEN%20OR%20%22gene%20editing%22%20OR%20%22gene-edited%22%20OR%20%22base%20edited%22%29%20AND%20%28CAR%20OR%20TCR%20OR%20%22T%20cell%22%29&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of ANGPTL3 (zodasiran, solbinsiran) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=zodasiran%20OR%20ARO-ANG3%20OR%20solbinsiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis or Crohn's disease with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in prostate cancer, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&query.cond=prostate&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in colorectal cancer, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&query.cond=colorectal%20OR%20colon%20OR%20rectal&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in breast cancer, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&query.cond=%22breast%20cancer%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Actinium-225 agents (alpha) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Actinium%20OR%20225Ac%20OR%20Ac-225&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of BL-B01D1 (EGFR x HER3 bispecific ADC) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=BL-B01D1%20OR%20izalontamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-26, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Actinium-225 agents (alpha) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Actinium%20OR%20225Ac%20OR%20Ac-225&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in immune thrombocytopenia or autoimmune haemolytic anaemia, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=%22immune%20thrombocytopenia%22%20OR%20%22autoimmune%20hemolytic%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CagriSema / cagrilintide (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=cagrilintide%20OR%20CagriSema&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist or a GLP-1-based multi-agonist (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, mazdutide, MariTide, amycretin and others, including development codes) in obesity or overweight, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&query.cond=obesity%20OR%20overweight&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Obicetrapib (CETP) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=obicetrapib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Oral PCSK9 inhibitors (enlicitide, AZD0780) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=enlicitide%20OR%20MK-0616%20OR%20AZD0780&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Lutetium-177 agents (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in heart failure or cardiovascular disease, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&query.cond=%22heart%20failure%22%20OR%20cardiovascular%20OR%20atherosclerosis&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Anti-TL1A antibodies (within: interventional drug or biologic studies in ulcerative colitis or Crohn's disease) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=tulisokibart%20OR%20MK-7240%20OR%20PRA023%20OR%20duvakitug%20OR%20TEV-48574%20OR%20afimkibart%20OR%20RVT-3101%20OR%20RO7790121%20OR%20TL1A&query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Adagrasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=adagrasib%20OR%20MRTX849&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in breast cancer, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22&query.cond=%22breast%20cancer%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Radium-223 (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis or Crohn's disease with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Agitation and psychosis in Alzheimer's (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=brexpiprazole%20OR%20AXS-05%20OR%20pimavanserin%20OR%20xanomeline%20OR%20masupirdine%20OR%20dextromethorphan&query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of T-cell engagers (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab%20OR%20%22T%20cell%20engager%22&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in lymphoma, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=lymphoma&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of PSMA-targeted (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=PSMA%20AND%20%28Lutetium%20OR%20177Lu%20OR%20Actinium%20OR%20225Ac%20OR%20212Pb%29&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis or Crohn's disease with a start date from 2023-01-01 to 2026-09-26, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis or Crohn's disease in ulcerative colitis, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in pancreatic cancer, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&query.cond=pancreatic&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Pumitamig / BNT327 (PD-L1 x VEGF) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=pumitamig%20OR%20BNT327%20OR%20PM8002&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Divarasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=divarasib%20OR%20GDC-6036&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in multiple myeloma, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab&query.cond=myeloma&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of IL-23 p19 antibodies (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=guselkumab%20OR%20mirikizumab%20OR%20risankizumab%20OR%20tildrakizumab&query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of BCMA x CD3 T-cell engagers (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=teclistamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20etentamig%20OR%20ABBV-383&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Lp(a) lowering (olpasiran, lepodisiran, zerlasiran, pelacarsen, muvalaplin) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20SLN360%20OR%20pelacarsen%20OR%20TQJ230%20OR%20muvalaplin&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Olomorasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=olomorasib%20OR%20LY3537982&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of Obicetrapib (CETP) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=obicetrapib&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic sclerosis, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=%22systemic%20sclerosis%22%20OR%20scleroderma&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist or a GLP-1-based multi-agonist (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in the United States", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in prostate cancer, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&query.cond=prostate&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in breast cancer, with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=%22breast%20cancer%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-26, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: All interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product, any start date, as registered on 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of PD-(L)1 x VEGF bispecifics (all) (any indication) with a start date from 2023-01-01 to 2026-09-27", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=ivonescimab%20OR%20AK112%20OR%20SMT112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20PF-08634404&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of BCMA x CD3 T-cell engagers (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=teclistamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20etentamig%20OR%20ABBV-383&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in cancer, with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 }, { "title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "statistic_count": 1 }, { "title": "ClinicalTrials.gov study count: Interventional studies of SHR-A1811 / trastuzumab rezetecan (HER2) (any indication) with a start date from 2023-01-01 to 2026-09-26", "url": "https://clinicaltrials.gov/api/v2/studies?query.intr=SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-26%5D&countTotal=true&pageSize=1&fields=NCTId", "doc_type": "dataset", "published_date": null, "accessed_at": "2026-09-26", "license": "public-domain", "url_status": "ok", "statistic_count": 0 } ], "statistics": [ { "id": "stat_6PPPXE3T4FANCXDXZ9P6G2YPKA", "url": "https://statorigin.org/stat/stat_6PPPXE3T4FANCXDXZ9P6G2YPKA", "indicator": { "slug": "ctgov-alz-active-trials", "name": "Active Alzheimer's disease drug trials", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose overall status is recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-09-27", "end": "2026-09-27", "type": "point" }, "value": 280, "value_text": "280 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27.", "quote": "{\"totalCount\":280,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_GBM19D4E5D40S47HWJXQ0J6MGW", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_6PPPXE3T4FANCXDXZ9P6G2YPKA", "bibtex": "@misc{clinicaltrialsgo2026ctgovg2ypka,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_6PPPXE3T4FANCXDXZ9P6G2YPKA},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\&filter.overallStatus=RECRUITING\\%2CNOT\\_YET\\_RECRUITING\\%2CACTIVE\\_NOT\\_RECRUITING\\%2CENROLLING\\_BY\\_INVITATION\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_AMY20EM2RNW8Q9RJFE4WN91N7E", "url": "https://statorigin.org/stat/stat_AMY20EM2RNW8Q9RJFE4WN91N7E", "indicator": { "slug": "ctgov-glp1-active-trials", "name": "Active GLP-1, incretin multi-agonist and amylin trials", "definition": "Count of interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) whose overall status is recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-09-27", "end": "2026-09-27", "type": "point" }, "value": 600, "value_text": "600 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27.", "quote": "{\"totalCount\":600,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_H2J37R3RP64F5N7DM8EF25RM6S", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_AMY20EM2RNW8Q9RJFE4WN91N7E", "bibtex": "@misc{clinicaltrialsgo2026ctgovn91n7e,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_AMY20EM2RNW8Q9RJFE4WN91N7E},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide\\%20OR\\%20tirzepatide\\%20OR\\%20retatrutide\\%20OR\\%20orforglipron\\%20OR\\%20survodutide\\%20OR\\%20cagrilintide\\%20OR\\%20CagriSema\\%20OR\\%20mazdutide\\%20OR\\%20liraglutide\\%20OR\\%20dulaglutide\\%20OR\\%20exenatide\\%20OR\\%20ecnoglutide\\%20OR\\%20danuglipron\\%20OR\\%20pemvidutide\\%20OR\\%20amycretin\\%20OR\\%20efinopegdutide\\%20OR\\%20MariTide\\%20OR\\%20maridebart\\%20OR\\%20petrelintide\\%20OR\\%20\\%22GLP-1\\%20receptor\\%20agonist\\%22\\%20OR\\%20LY3437943\\%20OR\\%20LY3502970\\%20OR\\%20\\%22BI\\%20456906\\%22\\%20OR\\%20LY3298176\\%20OR\\%20IBI362\\%20OR\\%20\\%22AMG\\%20133\\%22\\%20OR\\%20\\%22NNC0487-0111\\%22\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\&filter.overallStatus=RECRUITING\\%2CNOT\\_YET\\_RECRUITING\\%2CACTIVE\\_NOT\\_RECRUITING\\%2CENROLLING\\_BY\\_INVITATION\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_XFAZ1AKKBC796V287H8GWRH1NF", "url": "https://statorigin.org/stat/stat_XFAZ1AKKBC796V287H8GWRH1NF", "indicator": { "slug": "ctgov-kras-active-trials", "name": "Active KRAS and RAS inhibitor trials", "definition": "Count of interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) whose overall status is recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-09-27", "end": "2026-09-27", "type": "point" }, "value": 217, "value_text": "217 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27.", "quote": "{\"totalCount\":217,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_RPRCVGAP4EV8M21H9H2HBC7BB8", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_XFAZ1AKKBC796V287H8GWRH1NF", "bibtex": "@misc{clinicaltrialsgo2026ctgovwrh1nf,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_XFAZ1AKKBC796V287H8GWRH1NF},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib\\%20OR\\%20adagrasib\\%20OR\\%20divarasib\\%20OR\\%20daraxonrasib\\%20OR\\%20RMC-6236\\%20OR\\%20elironrasib\\%20OR\\%20RMC-6291\\%20OR\\%20zoldonrasib\\%20OR\\%20RMC-9805\\%20OR\\%20olomorasib\\%20OR\\%20garsorasib\\%20OR\\%20fulzerasib\\%20OR\\%20glecirasib\\%20OR\\%20MRTX1133\\%20OR\\%20\\%22KRAS\\%20G12C\\%20inhibitor\\%22\\%20OR\\%20\\%22KRAS\\%20G12D\\%20inhibitor\\%22\\%20OR\\%20\\%22pan-KRAS\\%22\\%20OR\\%20\\%22pan-RAS\\%22\\%20OR\\%20\\%22KRAS\\%20inhibitor\\%22\\%20OR\\%20opnurasib\\%20OR\\%20D-1553\\%20OR\\%20LY3537982\\%20OR\\%20HRS-4642\\%20OR\\%20INCB161734\\%20OR\\%20ASP3082\\%20OR\\%20setidegrasib\\%20OR\\%20\\%22AMG\\%20510\\%22\\%20OR\\%20MRTX849\\%20OR\\%20GDC-6036\\%20OR\\%20G12D\\%20OR\\%20GFH925\\%20OR\\%20IBI351\\%20OR\\%20JAB-21822\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\&filter.overallStatus=RECRUITING\\%2CNOT\\_YET\\_RECRUITING\\%2CACTIVE\\_NOT\\_RECRUITING\\%2CENROLLING\\_BY\\_INVITATION\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_QJW9P6YX84YVWJ3XHCYXJAPZ8Y", "url": "https://statorigin.org/stat/stat_QJW9P6YX84YVWJ3XHCYXJAPZ8Y", "indicator": { "slug": "ctgov-adc-active-trials", "name": "Active antibody-drug conjugate trials", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose overall status is recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-09-27", "end": "2026-09-27", "type": "point" }, "value": 1488, "value_text": "1,488 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27.", "quote": "{\"totalCount\":1488,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_MQBCF47ZYKFXTWQYE4PD2BG7JS", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_QJW9P6YX84YVWJ3XHCYXJAPZ8Y", "bibtex": "@misc{clinicaltrialsgo2026ctgovjapz8y,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_QJW9P6YX84YVWJ3XHCYXJAPZ8Y},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\&filter.overallStatus=RECRUITING\\%2CNOT\\_YET\\_RECRUITING\\%2CACTIVE\\_NOT\\_RECRUITING\\%2CENROLLING\\_BY\\_INVITATION\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_2VJN8ZPTQ005ETYVT2V6KVAPJN", "url": "https://statorigin.org/stat/stat_2VJN8ZPTQ005ETYVT2V6KVAPJN", "indicator": { "slug": "ctgov-autoimmune-active-trials", "name": "Active autoimmune cell therapy and T-cell engager trials", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose overall status is recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-09-27", "end": "2026-09-27", "type": "point" }, "value": 279, "value_text": "279 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27.", "quote": "{\"totalCount\":279,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_PX26M0KJDZDAFFZKF4N1ESTZ0S", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_2VJN8ZPTQ005ETYVT2V6KVAPJN", "bibtex": "@misc{clinicaltrialsgo2026ctgovkvapjn,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_2VJN8ZPTQ005ETYVT2V6KVAPJN},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\&filter.overallStatus=RECRUITING\\%2CNOT\\_YET\\_RECRUITING\\%2CACTIVE\\_NOT\\_RECRUITING\\%2CENROLLING\\_BY\\_INVITATION\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_KCBHZA0K207AE9YK10PCPCGJ3P", "url": "https://statorigin.org/stat/stat_KCBHZA0K207AE9YK10PCPCGJ3P", "indicator": { "slug": "ctgov-rnacv-active-trials", "name": "Active cardiometabolic RNA and next-generation lipid drug trials", "definition": "Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose overall status is recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-09-27", "end": "2026-09-27", "type": "point" }, "value": 90, "value_text": "90 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27.", "quote": "{\"totalCount\":90,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_5KPQSAQCG1GFA1YDAGZEJTQJS7", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_KCBHZA0K207AE9YK10PCPCGJ3P", "bibtex": "@misc{clinicaltrialsgo2026ctgovpcgj3p,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_KCBHZA0K207AE9YK10PCPCGJ3P},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran\\%20OR\\%20olpasiran\\%20OR\\%20lepodisiran\\%20OR\\%20zerlasiran\\%20OR\\%20pelacarsen\\%20OR\\%20muvalaplin\\%20OR\\%20zilebesiran\\%20OR\\%20plozasiran\\%20OR\\%20zodasiran\\%20OR\\%20solbinsiran\\%20OR\\%20olezarsen\\%20OR\\%20volanesorsen\\%20OR\\%20SLN360\\%20OR\\%20ARO-APOC3\\%20OR\\%20ARO-ANG3\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20lerodalcibep\\%20OR\\%20enlicitide\\%20OR\\%20MK-0616\\%20OR\\%20obicetrapib\\%20OR\\%20AZD0780\\%20OR\\%20vutrisiran\\%20OR\\%20patisiran\\%20OR\\%20eplontersen\\%20OR\\%20nucresiran\\%20OR\\%20TQJ230\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\&filter.overallStatus=RECRUITING\\%2CNOT\\_YET\\_RECRUITING\\%2CACTIVE\\_NOT\\_RECRUITING\\%2CENROLLING\\_BY\\_INVITATION\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_28PJ276D5XMYWC49FPGHVPZCWJ", "url": "https://statorigin.org/stat/stat_28PJ276D5XMYWC49FPGHVPZCWJ", "indicator": { "slug": "ctgov-gene-active-trials", "name": "Active gene editing trials", "definition": "Count of interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product whose overall status is recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-09-27", "end": "2026-09-27", "type": "point" }, "value": 131, "value_text": "131 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27.", "quote": "{\"totalCount\":131,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_KVEA6FWWF66DKFF7GKQW5D1S7N", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_28PJ276D5XMYWC49FPGHVPZCWJ", "bibtex": "@misc{clinicaltrialsgo2026ctgovvpzcwj,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_28PJ276D5XMYWC49FPGHVPZCWJ},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR\\%20OR\\%20Cas9\\%20OR\\%20Cas12\\%20OR\\%20\\%22base\\%20editing\\%22\\%20OR\\%20\\%22base\\%20editor\\%22\\%20OR\\%20\\%22prime\\%20editing\\%22\\%20OR\\%20\\%22gene\\%20editing\\%22\\%20OR\\%20\\%22genome\\%20editing\\%22\\%20OR\\%20\\%22zinc\\%20finger\\%20nuclease\\%22\\%20OR\\%20TALEN\\%20OR\\%20exagamglogene\\%20OR\\%20NTLA-2001\\%20OR\\%20NTLA-2002\\%20OR\\%20nexiguran\\%20OR\\%20lonvoguran\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20BEAM-101\\%20OR\\%20BEAM-302\\%20OR\\%20EBT-101\\%20OR\\%20EDIT-101\\%20OR\\%20CTX310\\%20OR\\%20\\%22epigenetic\\%20editing\\%22\\%20OR\\%20CTX320\\%20OR\\%20YOLT-101\\%20OR\\%20YOLT-201\\%20OR\\%20ART001\\%20OR\\%20CS-101\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\&filter.overallStatus=RECRUITING\\%2CNOT\\_YET\\_RECRUITING\\%2CACTIVE\\_NOT\\_RECRUITING\\%2CENROLLING\\_BY\\_INVITATION\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_CX3D9R62NDQE4RFA5E4F9A0RPE", "url": "https://statorigin.org/stat/stat_CX3D9R62NDQE4RFA5E4F9A0RPE", "indicator": { "slug": "ctgov-ibd-active-trials", "name": "Active inflammatory bowel disease drug trials", "definition": "Count of interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified whose overall status is recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-09-27", "end": "2026-09-27", "type": "point" }, "value": 372, "value_text": "372 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27.", "quote": "{\"totalCount\":372,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_M3KZBRCNWGYVT62TRWP2Y1GSF1", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=%22ulcerative%20colitis%22%20OR%20%22Crohn%20disease%22%20OR%20%22Crohn%27s%20disease%22%20OR%20%22inflammatory%20bowel%20disease%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_CX3D9R62NDQE4RFA5E4F9A0RPE", "bibtex": "@misc{clinicaltrialsgo2026ctgov9a0rpe,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_CX3D9R62NDQE4RFA5E4F9A0RPE},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=\\%22ulcerative\\%20colitis\\%22\\%20OR\\%20\\%22Crohn\\%20disease\\%22\\%20OR\\%20\\%22Crohn\\%27s\\%20disease\\%22\\%20OR\\%20\\%22inflammatory\\%20bowel\\%20disease\\%22\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\&filter.overallStatus=RECRUITING\\%2CNOT\\_YET\\_RECRUITING\\%2CACTIVE\\_NOT\\_RECRUITING\\%2CENROLLING\\_BY\\_INVITATION\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_9BSGEKK7CJ1V8AW4DBVJTW3PZ2", "url": "https://statorigin.org/stat/stat_9BSGEKK7CJ1V8AW4DBVJTW3PZ2", "indicator": { "slug": "ctgov-bsab-active-trials", "name": "Active oncology bispecific antibody trials", "definition": "Count of interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) whose overall status is recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-09-27", "end": "2026-09-27", "type": "point" }, "value": 1109, "value_text": "1,109 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27.", "quote": "{\"totalCount\":1109,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_SDXRDXDN3NM6ZBRSGTA17RQDGX", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_9BSGEKK7CJ1V8AW4DBVJTW3PZ2", "bibtex": "@misc{clinicaltrialsgo2026ctgovtw3pz2,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_9BSGEKK7CJ1V8AW4DBVJTW3PZ2},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=bispecific\\%20OR\\%20ivonescimab\\%20OR\\%20cadonilimab\\%20OR\\%20AK112\\%20OR\\%20PM8002\\%20OR\\%20BNT327\\%20OR\\%20pumitamig\\%20OR\\%20SSGJ-707\\%20OR\\%20zanidatamab\\%20OR\\%20amivantamab\\%20OR\\%20tarlatamab\\%20OR\\%20epcoritamab\\%20OR\\%20glofitamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20teclistamab\\%20OR\\%20talquetamab\\%20OR\\%20elranatamab\\%20OR\\%20linvoseltamab\\%20OR\\%20SMT112\\%20OR\\%20PF-08634404\\%20OR\\%20AK104\\%20OR\\%20odronextamab\\%20OR\\%20etentamig\\%20OR\\%20ABBV-383\\&query.cond=cancer\\%20OR\\%20tumor\\%20OR\\%20neoplasm\\%20OR\\%20carcinoma\\%20OR\\%20lymphoma\\%20OR\\%20leukemia\\%20OR\\%20myeloma\\%20OR\\%20malignancy\\%20OR\\%20\\%22solid\\%20tumor\\%22\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\&filter.overallStatus=RECRUITING\\%2CNOT\\_YET\\_RECRUITING\\%2CACTIVE\\_NOT\\_RECRUITING\\%2CENROLLING\\_BY\\_INVITATION\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_TB74KKKNJ4B878TT6RK5XF7QTH", "url": "https://statorigin.org/stat/stat_TB74KKKNJ4B878TT6RK5XF7QTH", "indicator": { "slug": "ctgov-rlt-active-trials", "name": "Active radioligand therapy trials", "definition": "Count of interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy whose overall status is recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-09-27", "end": "2026-09-27", "type": "point" }, "value": 323, "value_text": "323 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27.", "quote": "{\"totalCount\":323,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_YV53FZVM9VW5JAS05RHH1RP2B7", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_TB74KKKNJ4B878TT6RK5XF7QTH", "bibtex": "@misc{clinicaltrialsgo2026ctgovxf7qth,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_TB74KKKNJ4B878TT6RK5XF7QTH},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium\\%20OR\\%20177Lu\\%20OR\\%20Lu-177\\%20OR\\%20Actinium\\%20OR\\%20225Ac\\%20OR\\%20Ac-225\\%20OR\\%20\\%22Radium-223\\%22\\%20OR\\%20\\%22Radium\\%20223\\%22\\%20OR\\%20212Pb\\%20OR\\%20Pb-212\\%20OR\\%20\\%22radioligand\\%20therapy\\%22\\%20OR\\%20\\%22PSMA-617\\%22\\%20OR\\%20Terbium\\%20OR\\%20\\%22Copper-67\\%22\\%20OR\\%20\\%22lead-212\\%22\\%20OR\\%20Xofigo\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\&filter.overallStatus=RECRUITING\\%2CNOT\\_YET\\_RECRUITING\\%2CACTIVE\\_NOT\\_RECRUITING\\%2CENROLLING\\_BY\\_INVITATION\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_YD0YFD943JW19WNZCPEJ9ZEAZ3", "url": "https://statorigin.org/stat/stat_YD0YFD943JW19WNZCPEJ9ZEAZ3", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 58, "value_text": "58 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country.", "quote": "{\"totalCount\":58,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2023). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_YD0YFD943JW19WNZCPEJ9ZEAZ3", "bibtex": "@misc{clinicaltrialsgo2023ctgov9zeaz3,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_YD0YFD943JW19WNZCPEJ9ZEAZ3},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2023-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_PAX1RFYAXSGTFJHQZJ2A7ZVB4E", "url": "https://statorigin.org/stat/stat_PAX1RFYAXSGTFJHQZJ2A7ZVB4E", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 16, "value_text": "16 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":16,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2025). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_PAX1RFYAXSGTFJHQZJ2A7ZVB4E", "bibtex": "@misc{clinicaltrialsgo2025ctgov7zvb4e,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_PAX1RFYAXSGTFJHQZJ2A7ZVB4E},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2025-01-01\\%2C2025-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_CEASHSJWYQ3E0PTBY63C3F6WSX", "url": "https://statorigin.org/stat/stat_CEASHSJWYQ3E0PTBY63C3F6WSX", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 30, "value_text": "30 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":30,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2023). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_CEASHSJWYQ3E0PTBY63C3F6WSX", "bibtex": "@misc{clinicaltrialsgo2023ctgov3f6wsx,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_CEASHSJWYQ3E0PTBY63C3F6WSX},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2023-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_J28CVWA0ST64CQ9ZQNV3SVPY3P", "url": "https://statorigin.org/stat/stat_J28CVWA0ST64CQ9ZQNV3SVPY3P", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 81, "value_text": "81 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country.", "quote": "{\"totalCount\":81,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2022). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_J28CVWA0ST64CQ9ZQNV3SVPY3P", "bibtex": "@misc{clinicaltrialsgo2022ctgovsvpy3p,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_J28CVWA0ST64CQ9ZQNV3SVPY3P},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2022-01-01\\%2C2022-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_C9FED2GXNN5HNZCWEAV98BPYBR", "url": "https://statorigin.org/stat/stat_C9FED2GXNN5HNZCWEAV98BPYBR", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2020-01-01", "end": "2020-12-31", "type": "year" }, "value": 37, "value_text": "37 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":37,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2020). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_C9FED2GXNN5HNZCWEAV98BPYBR", "bibtex": "@misc{clinicaltrialsgo2020ctgov8bpybr,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States},\n year = {2020},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_C9FED2GXNN5HNZCWEAV98BPYBR},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2020-01-01\\%2C2020-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_75CVXRHYA5XSB6A5CF47HC9SNA", "url": "https://statorigin.org/stat/stat_75CVXRHYA5XSB6A5CF47HC9SNA", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 50, "value_text": "50 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":50,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2022). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_75CVXRHYA5XSB6A5CF47HC9SNA", "bibtex": "@misc{clinicaltrialsgo2022ctgovhc9sna,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_75CVXRHYA5XSB6A5CF47HC9SNA},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2022-01-01\\%2C2022-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_GQ04QX6Z5CPGH4ANRKBR8K7R44", "url": "https://statorigin.org/stat/stat_GQ04QX6Z5CPGH4ANRKBR8K7R44", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 14, "value_text": "14 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":14,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2024). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_GQ04QX6Z5CPGH4ANRKBR8K7R44", "bibtex": "@misc{clinicaltrialsgo2024ctgov8k7r44,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_GQ04QX6Z5CPGH4ANRKBR8K7R44},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2024-01-01\\%2C2024-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_48BP00JD246B416R8WB5EZ65TZ", "url": "https://statorigin.org/stat/stat_48BP00JD246B416R8WB5EZ65TZ", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 38, "value_text": "38 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":38,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2024). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_48BP00JD246B416R8WB5EZ65TZ", "bibtex": "@misc{clinicaltrialsgo2024ctgovez65tz,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_48BP00JD246B416R8WB5EZ65TZ},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2024-01-01\\%2C2024-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_Q4CMK3806CMTQT6M9NTBSH4REN", "url": "https://statorigin.org/stat/stat_Q4CMK3806CMTQT6M9NTBSH4REN", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2021-01-01", "end": "2021-12-31", "type": "year" }, "value": 12, "value_text": "12 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":12,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2021). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_Q4CMK3806CMTQT6M9NTBSH4REN", "bibtex": "@misc{clinicaltrialsgo2021ctgovsh4ren,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China},\n year = {2021},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_Q4CMK3806CMTQT6M9NTBSH4REN},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2021-01-01\\%2C2021-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_T5HTCK4E6F8MC791J2H7VT9YA3", "url": "https://statorigin.org/stat/stat_T5HTCK4E6F8MC791J2H7VT9YA3", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 5, "value_text": "5 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":5,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2023). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_T5HTCK4E6F8MC791J2H7VT9YA3", "bibtex": "@misc{clinicaltrialsgo2023ctgovvt9ya3,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_T5HTCK4E6F8MC791J2H7VT9YA3},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2023-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_DH9HEZCNZ44JN2P8Q4YE0KTAWV", "url": "https://statorigin.org/stat/stat_DH9HEZCNZ44JN2P8Q4YE0KTAWV", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2020-01-01", "end": "2020-12-31", "type": "year" }, "value": 6, "value_text": "6 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":6,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2020). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_DH9HEZCNZ44JN2P8Q4YE0KTAWV", "bibtex": "@misc{clinicaltrialsgo2020ctgov0ktawv,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China},\n year = {2020},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_DH9HEZCNZ44JN2P8Q4YE0KTAWV},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2020-01-01\\%2C2020-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_35P2B9SY6DR1C2CPBQJ6WHGEMB", "url": "https://statorigin.org/stat/stat_35P2B9SY6DR1C2CPBQJ6WHGEMB", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 71, "value_text": "71 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in any country.", "quote": "{\"totalCount\":71,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2024). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_35P2B9SY6DR1C2CPBQJ6WHGEMB", "bibtex": "@misc{clinicaltrialsgo2024ctgovwhgemb,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in any country},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_35P2B9SY6DR1C2CPBQJ6WHGEMB},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2024-01-01\\%2C2024-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_PGJVRNXPGHRWDNG7XZWNZNJPZX", "url": "https://statorigin.org/stat/stat_PGJVRNXPGHRWDNG7XZWNZNJPZX", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 34, "value_text": "34 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":34,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2025). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_PGJVRNXPGHRWDNG7XZWNZNJPZX", "bibtex": "@misc{clinicaltrialsgo2025ctgovznjpzx,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_PGJVRNXPGHRWDNG7XZWNZNJPZX},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2025-01-01\\%2C2025-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_056BC1CQNR96PKVS29TJ6DEN8N", "url": "https://statorigin.org/stat/stat_056BC1CQNR96PKVS29TJ6DEN8N", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2020-01-01", "end": "2020-12-31", "type": "year" }, "value": 66, "value_text": "66 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in any country.", "quote": "{\"totalCount\":66,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2020). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_056BC1CQNR96PKVS29TJ6DEN8N", "bibtex": "@misc{clinicaltrialsgo2020ctgov6den8n,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in any country},\n year = {2020},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_056BC1CQNR96PKVS29TJ6DEN8N},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2020-01-01\\%2C2020-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_Q553ZB2ETK49270PBQP8R0KTP0", "url": "https://statorigin.org/stat/stat_Q553ZB2ETK49270PBQP8R0KTP0", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 78, "value_text": "78 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country.", "quote": "{\"totalCount\":78,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2025). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_Q553ZB2ETK49270PBQP8R0KTP0", "bibtex": "@misc{clinicaltrialsgo2025ctgovr0ktp0,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_Q553ZB2ETK49270PBQP8R0KTP0},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2025-01-01\\%2C2025-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_S146KD2AD5QHB08KR09F79GJZD", "url": "https://statorigin.org/stat/stat_S146KD2AD5QHB08KR09F79GJZD", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2021-01-01", "end": "2021-12-31", "type": "year" }, "value": 87, "value_text": "87 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country.", "quote": "{\"totalCount\":87,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2021). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_S146KD2AD5QHB08KR09F79GJZD", "bibtex": "@misc{clinicaltrialsgo2021ctgov79gjzd,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country},\n year = {2021},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_S146KD2AD5QHB08KR09F79GJZD},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2021-01-01\\%2C2021-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_B3HRK5W55QP5B1B7YCWE1ZRJ3Q", "url": "https://statorigin.org/stat/stat_B3HRK5W55QP5B1B7YCWE1ZRJ3Q", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2021-01-01", "end": "2021-12-31", "type": "year" }, "value": 56, "value_text": "56 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":56,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2021). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_B3HRK5W55QP5B1B7YCWE1ZRJ3Q", "bibtex": "@misc{clinicaltrialsgo2021ctgov1zrj3q,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States},\n year = {2021},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_B3HRK5W55QP5B1B7YCWE1ZRJ3Q},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2021-01-01\\%2C2021-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_R86Z83QSEP2TA0FTGSMXGEME16", "url": "https://statorigin.org/stat/stat_R86Z83QSEP2TA0FTGSMXGEME16", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 11, "value_text": "11 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":11,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2022). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_R86Z83QSEP2TA0FTGSMXGEME16", "bibtex": "@misc{clinicaltrialsgo2022ctgovgeme16,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_R86Z83QSEP2TA0FTGSMXGEME16},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2022-01-01\\%2C2022-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_K4FHEEAK9A4MCN41TB3AGQGKWP", "url": "https://statorigin.org/stat/stat_K4FHEEAK9A4MCN41TB3AGQGKWP", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 269, "value_text": "269 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country.", "quote": "{\"totalCount\":269,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_WSHFJCZ1QN6YGT5FC4H2PDMTHE", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_K4FHEEAK9A4MCN41TB3AGQGKWP", "bibtex": "@misc{clinicaltrialsgo2026ctgovgqgkwp,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_K4FHEEAK9A4MCN41TB3AGQGKWP},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_CZC5PK70VHDM25PPKKFBZ30TGX", "url": "https://statorigin.org/stat/stat_CZC5PK70VHDM25PPKKFBZ30TGX", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 128, "value_text": "128 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States.", "quote": "{\"totalCount\":128,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_V636PMTC5STKGFZJ6AFQAFHNH4", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_CZC5PK70VHDM25PPKKFBZ30TGX", "bibtex": "@misc{clinicaltrialsgo2026ctgovz30tgx,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_CZC5PK70VHDM25PPKKFBZ30TGX},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_10SWAB7MFZKQDR5TQV8AJGJBC3", "url": "https://statorigin.org/stat/stat_10SWAB7MFZKQDR5TQV8AJGJBC3", "indicator": { "slug": "ctgov-alz-trial-starts", "name": "Alzheimer's disease drug trial starts", "definition": "Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 46, "value_text": "46 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China.", "quote": "{\"totalCount\":46,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_2SQ89ATH83KDAX7ZVH6YKHMT5P", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20%28AREA%5BInterventionType%5DDRUG%20OR%20AREA%5BInterventionType%5DBIOLOGICAL%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_10SWAB7MFZKQDR5TQV8AJGJBC3", "bibtex": "@misc{clinicaltrialsgo2026ctgovjgjbc3,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_10SWAB7MFZKQDR5TQV8AJGJBC3},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20\\%28AREA\\%5BInterventionType\\%5DDRUG\\%20OR\\%20AREA\\%5BInterventionType\\%5DBIOLOGICAL\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_XA0N57X1V4350DCZW4H115YK61", "url": "https://statorigin.org/stat/stat_XA0N57X1V4350DCZW4H115YK61", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 150, "value_text": "150 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":150,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_0QBPRMSTMWB6E1204T5900GTMY", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2024). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_XA0N57X1V4350DCZW4H115YK61", "bibtex": "@misc{clinicaltrialsgo2024ctgov15yk61,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_XA0N57X1V4350DCZW4H115YK61},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2024-01-01\\%2C2024-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_HESYNQFER4H98R35ESD5J6R211", "url": "https://statorigin.org/stat/stat_HESYNQFER4H98R35ESD5J6R211", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2020-01-01", "end": "2020-12-31", "type": "year" }, "value": 73, "value_text": "73 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":73,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_K8BH16BAYZPCMVS1HWNSSPSYR1", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2020). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_HESYNQFER4H98R35ESD5J6R211", "bibtex": "@misc{clinicaltrialsgo2020ctgovj6r211,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States},\n year = {2020},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_HESYNQFER4H98R35ESD5J6R211},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2020-01-01\\%2C2020-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_83W3YHGNCQMM78TJ420A6WX0F2", "url": "https://statorigin.org/stat/stat_83W3YHGNCQMM78TJ420A6WX0F2", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 69, "value_text": "69 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":69,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_EH2HW2Q3NVSWYYJEZE5NJZPTBC", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2022). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_83W3YHGNCQMM78TJ420A6WX0F2", "bibtex": "@misc{clinicaltrialsgo2022ctgov6wx0f2,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_83W3YHGNCQMM78TJ420A6WX0F2},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2022-01-01\\%2C2022-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_8EBFGWZZKZ1DVYXVJYGX638XG3", "url": "https://statorigin.org/stat/stat_8EBFGWZZKZ1DVYXVJYGX638XG3", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2021-01-01", "end": "2021-12-31", "type": "year" }, "value": 145, "value_text": "145 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in any country.", "quote": "{\"totalCount\":145,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_ERNCEYFK3P3YGJTZSG25Q44R6B", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2021). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_8EBFGWZZKZ1DVYXVJYGX638XG3", "bibtex": "@misc{clinicaltrialsgo2021ctgov638xg3,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in any country},\n year = {2021},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_8EBFGWZZKZ1DVYXVJYGX638XG3},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2021-01-01\\%2C2021-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_S1S03CQH8803908HZW66Q4ZVHG", "url": "https://statorigin.org/stat/stat_S1S03CQH8803908HZW66Q4ZVHG", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 282, "value_text": "282 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in any country.", "quote": "{\"totalCount\":282,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_28E4RWBKPM3SQZFE41P7VSTR5V", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2024). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_S1S03CQH8803908HZW66Q4ZVHG", "bibtex": "@misc{clinicaltrialsgo2024ctgovq4zvhg,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in any country},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_S1S03CQH8803908HZW66Q4ZVHG},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2024-01-01\\%2C2024-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_NX644V1GQ6TPK5C2ZP2WX5PM92", "url": "https://statorigin.org/stat/stat_NX644V1GQ6TPK5C2ZP2WX5PM92", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2020-01-01", "end": "2020-12-31", "type": "year" }, "value": 101, "value_text": "101 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in any country.", "quote": "{\"totalCount\":101,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_3KWA1CX0HXFKXG4C81YC67KAP2", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2020). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_NX644V1GQ6TPK5C2ZP2WX5PM92", "bibtex": "@misc{clinicaltrialsgo2020ctgovx5pm92,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in any country},\n year = {2020},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_NX644V1GQ6TPK5C2ZP2WX5PM92},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2020-01-01\\%2C2020-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_AZ65X58YQGC2KPMMEZHVY1KB1T", "url": "https://statorigin.org/stat/stat_AZ65X58YQGC2KPMMEZHVY1KB1T", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2021-01-01", "end": "2021-12-31", "type": "year" }, "value": 40, "value_text": "40 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":40,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_1KC4ETKZGKB6JSX9NF6R2RXS0Z", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2021). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_AZ65X58YQGC2KPMMEZHVY1KB1T", "bibtex": "@misc{clinicaltrialsgo2021ctgovy1kb1t,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China},\n year = {2021},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_AZ65X58YQGC2KPMMEZHVY1KB1T},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2021-01-01\\%2C2021-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_476JH9062NQ5TFNZP6ZNG2DET0", "url": "https://statorigin.org/stat/stat_476JH9062NQ5TFNZP6ZNG2DET0", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 94, "value_text": "94 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":94,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_KNZP29FK937X4A6W5NEDMWRV2Z", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2023). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_476JH9062NQ5TFNZP6ZNG2DET0", "bibtex": "@misc{clinicaltrialsgo2023ctgovg2det0,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_476JH9062NQ5TFNZP6ZNG2DET0},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2023-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_VNYD84FDFYMEZCSD0B7REZZ06E", "url": "https://statorigin.org/stat/stat_VNYD84FDFYMEZCSD0B7REZZ06E", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2021-01-01", "end": "2021-12-31", "type": "year" }, "value": 94, "value_text": "94 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":94,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_3NW4S3FF9EAB2Q4F7KFV98ZCM2", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2021). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_VNYD84FDFYMEZCSD0B7REZZ06E", "bibtex": "@misc{clinicaltrialsgo2021ctgovezz06e,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States},\n year = {2021},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_VNYD84FDFYMEZCSD0B7REZZ06E},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2021-01-01\\%2C2021-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_PRGMBQFMG0NHPJPQC78WDCJBV7", "url": "https://statorigin.org/stat/stat_PRGMBQFMG0NHPJPQC78WDCJBV7", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2020-01-01", "end": "2020-12-31", "type": "year" }, "value": 25, "value_text": "25 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":25,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_YFF25B41S7S8G12FWQW0QJ1E29", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2020). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_PRGMBQFMG0NHPJPQC78WDCJBV7", "bibtex": "@misc{clinicaltrialsgo2020ctgovdcjbv7,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China},\n year = {2020},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_PRGMBQFMG0NHPJPQC78WDCJBV7},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2020-01-01\\%2C2020-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_A760494N531H3HTZY2TR50WW4B", "url": "https://statorigin.org/stat/stat_A760494N531H3HTZY2TR50WW4B", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 638, "value_text": "638 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China.", "quote": "{\"totalCount\":638,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_8D2MNN1RB7J4JSD30S904N7EBA", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_A760494N531H3HTZY2TR50WW4B", "bibtex": "@misc{clinicaltrialsgo2026ctgov50ww4b,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_A760494N531H3HTZY2TR50WW4B},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_KE381215ZVKM9Q563Y6CP5G6BE", "url": "https://statorigin.org/stat/stat_KE381215ZVKM9Q563Y6CP5G6BE", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 177, "value_text": "177 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":177,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_JHKKXF970WK21E9BDCZBNHNVQC", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2025). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_KE381215ZVKM9Q563Y6CP5G6BE", "bibtex": "@misc{clinicaltrialsgo2025ctgovp5g6be,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_KE381215ZVKM9Q563Y6CP5G6BE},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2025-01-01\\%2C2025-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_1G5RECEXVF4C20H6TBD0BNPP5S", "url": "https://statorigin.org/stat/stat_1G5RECEXVF4C20H6TBD0BNPP5S", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 96, "value_text": "96 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":96,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_CYMKFNCQX17SR2R7F742V8YSQ9", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2022). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_1G5RECEXVF4C20H6TBD0BNPP5S", "bibtex": "@misc{clinicaltrialsgo2022ctgovbnpp5s,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_1G5RECEXVF4C20H6TBD0BNPP5S},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2022-01-01\\%2C2022-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_93EFNGXPZVP14QGTMAQWAR0JAQ", "url": "https://statorigin.org/stat/stat_93EFNGXPZVP14QGTMAQWAR0JAQ", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 233, "value_text": "233 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in any country.", "quote": "{\"totalCount\":233,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_KDTSJW2X45JEWQH93J34KWJBY2", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2023). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_93EFNGXPZVP14QGTMAQWAR0JAQ", "bibtex": "@misc{clinicaltrialsgo2023ctgovar0jaq,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in any country},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_93EFNGXPZVP14QGTMAQWAR0JAQ},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2023-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_5G05C4071390GSGWEZ14J67AN3", "url": "https://statorigin.org/stat/stat_5G05C4071390GSGWEZ14J67AN3", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 144, "value_text": "144 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":144,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_KZB814PSRBZ6DHB59S4WCR6HCM", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2025). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_5G05C4071390GSGWEZ14J67AN3", "bibtex": "@misc{clinicaltrialsgo2025ctgovj67an3,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_5G05C4071390GSGWEZ14J67AN3},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2025-01-01\\%2C2025-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_RDZMKX1D527Q68MM9ZGQCFKP4E", "url": "https://statorigin.org/stat/stat_RDZMKX1D527Q68MM9ZGQCFKP4E", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 120, "value_text": "120 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":120,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_2Q2NRSVMAMYS4NT6E6YBTARNHA", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2023). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_RDZMKX1D527Q68MM9ZGQCFKP4E", "bibtex": "@misc{clinicaltrialsgo2023ctgovcfkp4e,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_RDZMKX1D527Q68MM9ZGQCFKP4E},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2023-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_92QJTV21AP3EFB9XRK10Y6M4DA", "url": "https://statorigin.org/stat/stat_92QJTV21AP3EFB9XRK10Y6M4DA", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 349, "value_text": "349 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in any country.", "quote": "{\"totalCount\":349,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_0ZJ8F1TNA7VVV48B3MT2BVYCV2", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2025). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_92QJTV21AP3EFB9XRK10Y6M4DA", "bibtex": "@misc{clinicaltrialsgo2025ctgovy6m4da,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in any country},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_92QJTV21AP3EFB9XRK10Y6M4DA},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2025-01-01\\%2C2025-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_GGHQZTVZBWE74PT76P67AJB5ED", "url": "https://statorigin.org/stat/stat_GGHQZTVZBWE74PT76P67AJB5ED", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 176, "value_text": "176 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country.", "quote": "{\"totalCount\":176,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_H8MA9MHCMVTVWN2NJPQSMMSP8F", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2022). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_GGHQZTVZBWE74PT76P67AJB5ED", "bibtex": "@misc{clinicaltrialsgo2022ctgovajb5ed,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_GGHQZTVZBWE74PT76P67AJB5ED},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2022-01-01\\%2C2022-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_DQT25GBABQ30DAQC2KHH9H39T4", "url": "https://statorigin.org/stat/stat_DQT25GBABQ30DAQC2KHH9H39T4", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 105, "value_text": "105 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":105,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_TB22QF71C78YRWMBKT2NRVCEE2", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2024). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_DQT25GBABQ30DAQC2KHH9H39T4", "bibtex": "@misc{clinicaltrialsgo2024ctgov9h39t4,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_DQT25GBABQ30DAQC2KHH9H39T4},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2024-01-01\\%2C2024-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_KZX3J5ZV6WJV38YKM1057T024C", "url": "https://statorigin.org/stat/stat_KZX3J5ZV6WJV38YKM1057T024C", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 428, "value_text": "428 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States.", "quote": "{\"totalCount\":428,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_4BK0QNSG6V544Y0FNKSQP2PZ57", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_KZX3J5ZV6WJV38YKM1057T024C", "bibtex": "@misc{clinicaltrialsgo2026ctgov7t024c,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_KZX3J5ZV6WJV38YKM1057T024C},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_R5WEE4YMW7X09GZRTB1Z7Q6Z3P", "url": "https://statorigin.org/stat/stat_R5WEE4YMW7X09GZRTB1Z7Q6Z3P", "indicator": { "slug": "ctgov-adc-trial-starts", "name": "Antibody-drug conjugate trial starts", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 1225, "value_text": "1,225 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in any country.", "quote": "{\"totalCount\":1225,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_XSYVGE0DWZK6ZJ3TMZD1V9X7G8", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_R5WEE4YMW7X09GZRTB1Z7Q6Z3P", "bibtex": "@misc{clinicaltrialsgo2026ctgov7q6z3p,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in any country},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_R5WEE4YMW7X09GZRTB1Z7Q6Z3P},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_MAX0F3F3XRXAC0D6X6PR4S77A3", "url": "https://statorigin.org/stat/stat_MAX0F3F3XRXAC0D6X6PR4S77A3", "indicator": { "slug": "ctgov-adc-trial-starts-breast", "name": "Antibody-drug conjugate trial starts since 2023: Breast cancer", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose conditions include breast cancer, started from 2023-01-01 to 2026-09-27." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 315, "value_text": "315 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in breast cancer, with a start date from 2023-01-01 to 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=%22breast%20cancer%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in breast cancer, with a start date from 2023-01-01 to 2026-09-27.", "quote": "{\"totalCount\":315,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_BYTMQWJ16NXB2H5MQ2KFWVJXC8", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in breast cancer, with a start date from 2023-01-01 to 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=%22breast%20cancer%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_MAX0F3F3XRXAC0D6X6PR4S77A3", "bibtex": "@misc{clinicaltrialsgo2026ctgov4s77a3,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in breast cancer, with a start date from 2023-01-01 to 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_MAX0F3F3XRXAC0D6X6PR4S77A3},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&query.cond=\\%22breast\\%20cancer\\%22\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_1GAA82R2Z6ZXMSDAGVA7RJB3GA", "url": "https://statorigin.org/stat/stat_1GAA82R2Z6ZXMSDAGVA7RJB3GA", "indicator": { "slug": "ctgov-adc-trial-starts-gastric", "name": "Antibody-drug conjugate trial starts since 2023: Gastric or oesophageal cancer", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose conditions include gastric or oesophageal cancer, started from 2023-01-01 to 2026-09-27." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 121, "value_text": "121 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in gastric or oesophageal cancer, with a start date from 2023-01-01 to 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=gastric%20OR%20stomach%20OR%20esophageal%20OR%20gastroesophageal&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in gastric or oesophageal cancer, with a start date from 2023-01-01 to 2026-09-27.", "quote": "{\"totalCount\":121,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_B0BHYSJAGY5MR8YDDCSZ6Q5C7X", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in gastric or oesophageal cancer, with a start date from 2023-01-01 to 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=gastric%20OR%20stomach%20OR%20esophageal%20OR%20gastroesophageal&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_1GAA82R2Z6ZXMSDAGVA7RJB3GA", "bibtex": "@misc{clinicaltrialsgo2026ctgovrjb3ga,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in gastric or oesophageal cancer, with a start date from 2023-01-01 to 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_1GAA82R2Z6ZXMSDAGVA7RJB3GA},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&query.cond=gastric\\%20OR\\%20stomach\\%20OR\\%20esophageal\\%20OR\\%20gastroesophageal\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_954CQYNWCC19647QT8A8RV7M6B", "url": "https://statorigin.org/stat/stat_954CQYNWCC19647QT8A8RV7M6B", "indicator": { "slug": "ctgov-adc-trial-starts-lung", "name": "Antibody-drug conjugate trial starts since 2023: Lung cancer", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose conditions include lung cancer, started from 2023-01-01 to 2026-09-27." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 193, "value_text": "193 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lung cancer, with a start date from 2023-01-01 to 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=%22lung%20cancer%22%20OR%20NSCLC%20OR%20SCLC&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lung cancer, with a start date from 2023-01-01 to 2026-09-27.", "quote": "{\"totalCount\":193,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_194Y79ZQ65A6KV97BXP75TNBJT", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lung cancer, with a start date from 2023-01-01 to 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=%22lung%20cancer%22%20OR%20NSCLC%20OR%20SCLC&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_954CQYNWCC19647QT8A8RV7M6B", "bibtex": "@misc{clinicaltrialsgo2026ctgovrv7m6b,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lung cancer, with a start date from 2023-01-01 to 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_954CQYNWCC19647QT8A8RV7M6B},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&query.cond=\\%22lung\\%20cancer\\%22\\%20OR\\%20NSCLC\\%20OR\\%20SCLC\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_NV4CD5XXQSNCCX7BF22A9K9P2Y", "url": "https://statorigin.org/stat/stat_NV4CD5XXQSNCCX7BF22A9K9P2Y", "indicator": { "slug": "ctgov-adc-trial-starts-lymphoma", "name": "Antibody-drug conjugate trial starts since 2023: Lymphoma", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose conditions include lymphoma, started from 2023-01-01 to 2026-09-27." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 119, "value_text": "119 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lymphoma, with a start date from 2023-01-01 to 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=lymphoma&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lymphoma, with a start date from 2023-01-01 to 2026-09-27.", "quote": "{\"totalCount\":119,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_1JA0SENC4185V1WX42D9504S3R", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lymphoma, with a start date from 2023-01-01 to 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=lymphoma&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_NV4CD5XXQSNCCX7BF22A9K9P2Y", "bibtex": "@misc{clinicaltrialsgo2026ctgov9k9p2y,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lymphoma, with a start date from 2023-01-01 to 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_NV4CD5XXQSNCCX7BF22A9K9P2Y},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&query.cond=lymphoma\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_598Z4RHVXS40NZ2313KN0P7027", "url": "https://statorigin.org/stat/stat_598Z4RHVXS40NZ2313KN0P7027", "indicator": { "slug": "ctgov-adc-trial-starts-gyn", "name": "Antibody-drug conjugate trial starts since 2023: Ovarian, cervical or endometrial cancer", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose conditions include ovarian, cervical or endometrial cancer, started from 2023-01-01 to 2026-09-27." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 195, "value_text": "195 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in ovarian, cervical or endometrial cancer, with a start date from 2023-01-01 to 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=ovarian%20OR%20cervical%20OR%20endometrial&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in ovarian, cervical or endometrial cancer, with a start date from 2023-01-01 to 2026-09-27.", "quote": "{\"totalCount\":195,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_RHVXK538YQS7FW2DW2D7SKQQP9", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in ovarian, cervical or endometrial cancer, with a start date from 2023-01-01 to 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=ovarian%20OR%20cervical%20OR%20endometrial&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_598Z4RHVXS40NZ2313KN0P7027", "bibtex": "@misc{clinicaltrialsgo2026ctgov0p7027,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in ovarian, cervical or endometrial cancer, with a start date from 2023-01-01 to 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_598Z4RHVXS40NZ2313KN0P7027},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&query.cond=ovarian\\%20OR\\%20cervical\\%20OR\\%20endometrial\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_TCN8MNW5X28JAAE0V9X0N0XNGQ", "url": "https://statorigin.org/stat/stat_TCN8MNW5X28JAAE0V9X0N0XNGQ", "indicator": { "slug": "ctgov-adc-trial-starts-urothelial", "name": "Antibody-drug conjugate trial starts since 2023: Urothelial or bladder cancer", "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose conditions include urothelial or bladder cancer, started from 2023-01-01 to 2026-09-27." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 116, "value_text": "116 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in urothelial or bladder cancer, with a start date from 2023-01-01 to 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=urothelial%20OR%20%22bladder%20cancer%22%20OR%20%22bladder%20carcinoma%22%20OR%20%22bladder%20neoplasm%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in urothelial or bladder cancer, with a start date from 2023-01-01 to 2026-09-27.", "quote": "{\"totalCount\":116,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_F4Y483KYXY6DBNH58P58S1809G", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in urothelial or bladder cancer, with a start date from 2023-01-01 to 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&query.cond=urothelial%20OR%20%22bladder%20cancer%22%20OR%20%22bladder%20carcinoma%22%20OR%20%22bladder%20neoplasm%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_TCN8MNW5X28JAAE0V9X0N0XNGQ", "bibtex": "@misc{clinicaltrialsgo2026ctgovn0xngq,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in urothelial or bladder cancer, with a start date from 2023-01-01 to 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_TCN8MNW5X28JAAE0V9X0N0XNGQ},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&query.cond=urothelial\\%20OR\\%20\\%22bladder\\%20cancer\\%22\\%20OR\\%20\\%22bladder\\%20carcinoma\\%22\\%20OR\\%20\\%22bladder\\%20neoplasm\\%22\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_0EFP4CHMJCGXRRG7MXKC4BXEZX", "url": "https://statorigin.org/stat/stat_0EFP4CHMJCGXRRG7MXKC4BXEZX", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 2, "value_text": "2 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":2,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2022). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_0EFP4CHMJCGXRRG7MXKC4BXEZX", "bibtex": "@misc{clinicaltrialsgo2022ctgov4bxezx,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_0EFP4CHMJCGXRRG7MXKC4BXEZX},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2022-01-01\\%2C2022-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_EW5VFNDWY3TV6FGBJ68XZ2FXFJ", "url": "https://statorigin.org/stat/stat_EW5VFNDWY3TV6FGBJ68XZ2FXFJ", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 27, "value_text": "27 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":27,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2024). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_EW5VFNDWY3TV6FGBJ68XZ2FXFJ", "bibtex": "@misc{clinicaltrialsgo2024ctgovz2fxfj,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_EW5VFNDWY3TV6FGBJ68XZ2FXFJ},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2024-01-01\\%2C2024-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_8V8SX72SW010ACM0A3YZ4KH8XK", "url": "https://statorigin.org/stat/stat_8V8SX72SW010ACM0A3YZ4KH8XK", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 91, "value_text": "91 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in any country.", "quote": "{\"totalCount\":91,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2024). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_8V8SX72SW010ACM0A3YZ4KH8XK", "bibtex": "@misc{clinicaltrialsgo2024ctgov4kh8xk,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in any country},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_8V8SX72SW010ACM0A3YZ4KH8XK},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2024-01-01\\%2C2024-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_G91KYBH4JRQPQHZ6EVXZNH60QF", "url": "https://statorigin.org/stat/stat_G91KYBH4JRQPQHZ6EVXZNH60QF", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 112, "value_text": "112 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in any country.", "quote": "{\"totalCount\":112,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2025). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_G91KYBH4JRQPQHZ6EVXZNH60QF", "bibtex": "@misc{clinicaltrialsgo2025ctgovnh60qf,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in any country},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_G91KYBH4JRQPQHZ6EVXZNH60QF},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2025-01-01\\%2C2025-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_ZAX3N5PN4EVZ4MPP38Z1DZVQP0", "url": "https://statorigin.org/stat/stat_ZAX3N5PN4EVZ4MPP38Z1DZVQP0", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2020-01-01", "end": "2020-12-31", "type": "year" }, "value": 1, "value_text": "1 study", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":1,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2020). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_ZAX3N5PN4EVZ4MPP38Z1DZVQP0", "bibtex": "@misc{clinicaltrialsgo2020ctgovdzvqp0,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States},\n year = {2020},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_ZAX3N5PN4EVZ4MPP38Z1DZVQP0},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2020-01-01\\%2C2020-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_AP5635J2TQH0Y5DQNSZZHVNMVE", "url": "https://statorigin.org/stat/stat_AP5635J2TQH0Y5DQNSZZHVNMVE", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 9, "value_text": "9 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":9,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2023). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_AP5635J2TQH0Y5DQNSZZHVNMVE", "bibtex": "@misc{clinicaltrialsgo2023ctgovhvnmve,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_AP5635J2TQH0Y5DQNSZZHVNMVE},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2023-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_8VZ6YY9FG7SZG9MWRQZ24AGSS2", "url": "https://statorigin.org/stat/stat_8VZ6YY9FG7SZG9MWRQZ24AGSS2", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2021-01-01", "end": "2021-12-31", "type": "year" }, "value": 0, "value_text": "0 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":0,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2021). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_8VZ6YY9FG7SZG9MWRQZ24AGSS2", "bibtex": "@misc{clinicaltrialsgo2021ctgov4agss2,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States},\n year = {2021},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_8VZ6YY9FG7SZG9MWRQZ24AGSS2},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2021-01-01\\%2C2021-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_QV308GCVEVRY0ENVQJTCA4JTX3", "url": "https://statorigin.org/stat/stat_QV308GCVEVRY0ENVQJTCA4JTX3", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2020-01-01", "end": "2020-12-31", "type": "year" }, "value": 2, "value_text": "2 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in any country.", "quote": "{\"totalCount\":2,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2020). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_QV308GCVEVRY0ENVQJTCA4JTX3", "bibtex": "@misc{clinicaltrialsgo2020ctgova4jtx3,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in any country},\n year = {2020},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_QV308GCVEVRY0ENVQJTCA4JTX3},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2020-01-01\\%2C2020-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_AV73A2V21E0ATENEWKDRMPVA9X", "url": "https://statorigin.org/stat/stat_AV73A2V21E0ATENEWKDRMPVA9X", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 21, "value_text": "21 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":21,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2025). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_AV73A2V21E0ATENEWKDRMPVA9X", "bibtex": "@misc{clinicaltrialsgo2025ctgovmpva9x,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_AV73A2V21E0ATENEWKDRMPVA9X},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2025-01-01\\%2C2025-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_5099EFZPBA19CVPG6FXYD9FG45", "url": "https://statorigin.org/stat/stat_5099EFZPBA19CVPG6FXYD9FG45", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 6, "value_text": "6 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in any country.", "quote": "{\"totalCount\":6,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2022). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_5099EFZPBA19CVPG6FXYD9FG45", "bibtex": "@misc{clinicaltrialsgo2022ctgovd9fg45,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in any country},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_5099EFZPBA19CVPG6FXYD9FG45},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2022-01-01\\%2C2022-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_6C89Q0JACJS4N4R7568DR37605", "url": "https://statorigin.org/stat/stat_6C89Q0JACJS4N4R7568DR37605", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 76, "value_text": "76 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":76,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2025). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_6C89Q0JACJS4N4R7568DR37605", "bibtex": "@misc{clinicaltrialsgo2025ctgovr37605,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_6C89Q0JACJS4N4R7568DR37605},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2025-01-01\\%2C2025-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_A0N90WGB8BEH2MKZ91697YWHH1", "url": "https://statorigin.org/stat/stat_A0N90WGB8BEH2MKZ91697YWHH1", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 17, "value_text": "17 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in any country.", "quote": "{\"totalCount\":17,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2023). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_A0N90WGB8BEH2MKZ91697YWHH1", "bibtex": "@misc{clinicaltrialsgo2023ctgov7ywhh1,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in any country},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_A0N90WGB8BEH2MKZ91697YWHH1},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2023-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_RA3WR3K8HGWSXC3X5PTNBBVNTJ", "url": "https://statorigin.org/stat/stat_RA3WR3K8HGWSXC3X5PTNBBVNTJ", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 51, "value_text": "51 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":51,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2024). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_RA3WR3K8HGWSXC3X5PTNBBVNTJ", "bibtex": "@misc{clinicaltrialsgo2024ctgovbbvntj,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_RA3WR3K8HGWSXC3X5PTNBBVNTJ},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2024-01-01\\%2C2024-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_HFHZXJPD95DADX4EABJNWH1JSZ", "url": "https://statorigin.org/stat/stat_HFHZXJPD95DADX4EABJNWH1JSZ", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 3, "value_text": "3 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":3,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2022). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_HFHZXJPD95DADX4EABJNWH1JSZ", "bibtex": "@misc{clinicaltrialsgo2022ctgovwh1jsz,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_HFHZXJPD95DADX4EABJNWH1JSZ},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2022-01-01\\%2C2022-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_RTFCBJP3PNAJDC7FC5FZF3BVAS", "url": "https://statorigin.org/stat/stat_RTFCBJP3PNAJDC7FC5FZF3BVAS", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 5, "value_text": "5 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":5,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2023). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_RTFCBJP3PNAJDC7FC5FZF3BVAS", "bibtex": "@misc{clinicaltrialsgo2023ctgovf3bvas,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_RTFCBJP3PNAJDC7FC5FZF3BVAS},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2023-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_NNTDP1KMKFZ66RDDQ90WEWVFZ4", "url": "https://statorigin.org/stat/stat_NNTDP1KMKFZ66RDDQ90WEWVFZ4", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2021-01-01", "end": "2021-12-31", "type": "year" }, "value": 6, "value_text": "6 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":6,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2021). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_NNTDP1KMKFZ66RDDQ90WEWVFZ4", "bibtex": "@misc{clinicaltrialsgo2021ctgovewvfz4,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China},\n year = {2021},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_NNTDP1KMKFZ66RDDQ90WEWVFZ4},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2021-01-01\\%2C2021-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_XTQS990FHNC06R71CAARRDRM8Y", "url": "https://statorigin.org/stat/stat_XTQS990FHNC06R71CAARRDRM8Y", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2020-01-01", "end": "2020-12-31", "type": "year" }, "value": 1, "value_text": "1 study", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":1,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2020). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_XTQS990FHNC06R71CAARRDRM8Y", "bibtex": "@misc{clinicaltrialsgo2020ctgovrdrm8y,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China},\n year = {2020},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_XTQS990FHNC06R71CAARRDRM8Y},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2020-01-01\\%2C2020-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_X2ETA1XPJVPWMJBSQN81FTD2YM", "url": "https://statorigin.org/stat/stat_X2ETA1XPJVPWMJBSQN81FTD2YM", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2021-01-01", "end": "2021-12-31", "type": "year" }, "value": 7, "value_text": "7 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in any country.", "quote": "{\"totalCount\":7,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2021). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_X2ETA1XPJVPWMJBSQN81FTD2YM", "bibtex": "@misc{clinicaltrialsgo2021ctgovftd2ym,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in any country},\n year = {2021},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_X2ETA1XPJVPWMJBSQN81FTD2YM},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2021-01-01\\%2C2021-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_MNJH86Y2YSB6Z6SVCKH6H19G6Y", "url": "https://statorigin.org/stat/stat_MNJH86Y2YSB6Z6SVCKH6H19G6Y", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 185, "value_text": "185 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China.", "quote": "{\"totalCount\":185,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_QH1YQN96ZA8863DEZ80SCYVZ53", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_MNJH86Y2YSB6Z6SVCKH6H19G6Y", "bibtex": "@misc{clinicaltrialsgo2026ctgovh19g6y,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_MNJH86Y2YSB6Z6SVCKH6H19G6Y},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_1JWSK5QA44R52PYDZ3YDZ2RD2G", "url": "https://statorigin.org/stat/stat_1JWSK5QA44R52PYDZ3YDZ2RD2G", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 67, "value_text": "67 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States.", "quote": "{\"totalCount\":67,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_38HWTWKE9KD8DWNZ50XQ7YY6ST", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_1JWSK5QA44R52PYDZ3YDZ2RD2G", "bibtex": "@misc{clinicaltrialsgo2026ctgovz2rd2g,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_1JWSK5QA44R52PYDZ3YDZ2RD2G},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_RKDJXK2XMR4GNYZ5C7E511T9M9", "url": "https://statorigin.org/stat/stat_RKDJXK2XMR4GNYZ5C7E511T9M9", "indicator": { "slug": "ctgov-autoimmune-trial-starts", "name": "Autoimmune cell therapy and T-cell engager trial starts", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 300, "value_text": "300 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in any country.", "quote": "{\"totalCount\":300,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_RYP5HM83PVQEJ3NV6SJJH47HA1", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_RKDJXK2XMR4GNYZ5C7E511T9M9", "bibtex": "@misc{clinicaltrialsgo2026ctgov11t9m9,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in any country},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_RKDJXK2XMR4GNYZ5C7E511T9M9},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_2QP0DW8JQGBMGCXQX6NXSC7DVN", "url": "https://statorigin.org/stat/stat_2QP0DW8JQGBMGCXQX6NXSC7DVN", "indicator": { "slug": "ctgov-autoimmune-trial-starts-itp", "name": "Autoimmune cell therapy and T-cell engager trial starts since 2023: Immune thrombocytopenia or autoimmune haemolytic anaemia", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose conditions include immune thrombocytopenia or autoimmune haemolytic anaemia, started from 2023-01-01 to 2026-09-27." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 26, "value_text": "26 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in immune thrombocytopenia or autoimmune haemolytic anaemia, with a start date from 2023-01-01 to 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=%22immune%20thrombocytopenia%22%20OR%20%22autoimmune%20hemolytic%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in immune thrombocytopenia or autoimmune haemolytic anaemia, with a start date from 2023-01-01 to 2026-09-27.", "quote": "{\"totalCount\":26,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_QQHCTC86SCGNPTXV84XK53EM53", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in immune thrombocytopenia or autoimmune haemolytic anaemia, with a start date from 2023-01-01 to 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=%22immune%20thrombocytopenia%22%20OR%20%22autoimmune%20hemolytic%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_2QP0DW8JQGBMGCXQX6NXSC7DVN", "bibtex": "@misc{clinicaltrialsgo2026ctgovsc7dvn,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in immune thrombocytopenia or autoimmune haemolytic anaemia, with a start date from 2023-01-01 to 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_2QP0DW8JQGBMGCXQX6NXSC7DVN},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20\\%22autoimmune\\%20hemolytic\\%22\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_ZKBX73DD1MG9H1TE3APKB85JZM", "url": "https://statorigin.org/stat/stat_ZKBX73DD1MG9H1TE3APKB85JZM", "indicator": { "slug": "ctgov-autoimmune-trial-starts-ms", "name": "Autoimmune cell therapy and T-cell engager trial starts since 2023: Multiple sclerosis", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose conditions include multiple sclerosis, started from 2023-01-01 to 2026-09-27." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 25, "value_text": "25 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in multiple sclerosis, with a start date from 2023-01-01 to 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=%22multiple%20sclerosis%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in multiple sclerosis, with a start date from 2023-01-01 to 2026-09-27.", "quote": "{\"totalCount\":25,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_PKVTQG551CQKESJCKT1ZGNVB32", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in multiple sclerosis, with a start date from 2023-01-01 to 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=%22multiple%20sclerosis%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_ZKBX73DD1MG9H1TE3APKB85JZM", "bibtex": "@misc{clinicaltrialsgo2026ctgovb85jzm,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in multiple sclerosis, with a start date from 2023-01-01 to 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_ZKBX73DD1MG9H1TE3APKB85JZM},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=\\%22multiple\\%20sclerosis\\%22\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_PH0XAF8RTJCABW5AMGZKEB104D", "url": "https://statorigin.org/stat/stat_PH0XAF8RTJCABW5AMGZKEB104D", "indicator": { "slug": "ctgov-autoimmune-trial-starts-mg", "name": "Autoimmune cell therapy and T-cell engager trial starts since 2023: Myasthenia gravis", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose conditions include myasthenia gravis, started from 2023-01-01 to 2026-09-27." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 29, "value_text": "29 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in myasthenia gravis, with a start date from 2023-01-01 to 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=myasthenia&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in myasthenia gravis, with a start date from 2023-01-01 to 2026-09-27.", "quote": "{\"totalCount\":29,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_F2ZAW74PK8XT823FCE5NH9J2MP", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in myasthenia gravis, with a start date from 2023-01-01 to 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=myasthenia&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_PH0XAF8RTJCABW5AMGZKEB104D", "bibtex": "@misc{clinicaltrialsgo2026ctgoveb104d,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in myasthenia gravis, with a start date from 2023-01-01 to 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_PH0XAF8RTJCABW5AMGZKEB104D},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=myasthenia\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_D84CWNJ48CE9WNDGTKDCZBT9VD", "url": "https://statorigin.org/stat/stat_D84CWNJ48CE9WNDGTKDCZBT9VD", "indicator": { "slug": "ctgov-autoimmune-trial-starts-sle", "name": "Autoimmune cell therapy and T-cell engager trial starts since 2023: Systemic lupus erythematosus / lupus nephritis", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose conditions include systemic lupus erythematosus / lupus nephritis, started from 2023-01-01 to 2026-09-27." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 147, "value_text": "147 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic lupus erythematosus / lupus nephritis, with a start date from 2023-01-01 to 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic lupus erythematosus / lupus nephritis, with a start date from 2023-01-01 to 2026-09-27.", "quote": "{\"totalCount\":147,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_WGYW9EBGKKVXRF9YYN2X970095", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic lupus erythematosus / lupus nephritis, with a start date from 2023-01-01 to 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_D84CWNJ48CE9WNDGTKDCZBT9VD", "bibtex": "@misc{clinicaltrialsgo2026ctgovzbt9vd,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic lupus erythematosus / lupus nephritis, with a start date from 2023-01-01 to 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_D84CWNJ48CE9WNDGTKDCZBT9VD},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_TVQSM5RYWAASHH98PJCME4X6N2", "url": "https://statorigin.org/stat/stat_TVQSM5RYWAASHH98PJCME4X6N2", "indicator": { "slug": "ctgov-autoimmune-trial-starts-ssc", "name": "Autoimmune cell therapy and T-cell engager trial starts since 2023: Systemic sclerosis", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose conditions include systemic sclerosis, started from 2023-01-01 to 2026-09-27." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 68, "value_text": "68 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic sclerosis, with a start date from 2023-01-01 to 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=%22systemic%20sclerosis%22%20OR%20scleroderma&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic sclerosis, with a start date from 2023-01-01 to 2026-09-27.", "quote": "{\"totalCount\":68,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_ZPSTXWD7P29M0ZYBV7XZDJQH2C", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic sclerosis, with a start date from 2023-01-01 to 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=%22systemic%20sclerosis%22%20OR%20scleroderma&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_TVQSM5RYWAASHH98PJCME4X6N2", "bibtex": "@misc{clinicaltrialsgo2026ctgove4x6n2,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic sclerosis, with a start date from 2023-01-01 to 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_TVQSM5RYWAASHH98PJCME4X6N2},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20scleroderma\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_VATM971KJ7BD1C16PQD0PCPK81", "url": "https://statorigin.org/stat/stat_VATM971KJ7BD1C16PQD0PCPK81", "indicator": { "slug": "ctgov-autoimmune-trial-starts-vasculitis", "name": "Autoimmune cell therapy and T-cell engager trial starts since 2023: Vasculitis", "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose conditions include vasculitis, started from 2023-01-01 to 2026-09-27." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 39, "value_text": "39 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in vasculitis, with a start date from 2023-01-01 to 2026-09-27", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=vasculitis&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in vasculitis, with a start date from 2023-01-01 to 2026-09-27.", "quote": "{\"totalCount\":39,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_Q69PB45WEVQZRAW0P9KBTH2H2M", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in vasculitis, with a start date from 2023-01-01 to 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=vasculitis&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_VATM971KJ7BD1C16PQD0PCPK81", "bibtex": "@misc{clinicaltrialsgo2026ctgovpcpk81,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in vasculitis, with a start date from 2023-01-01 to 2026-09-27},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_VATM971KJ7BD1C16PQD0PCPK81},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=vasculitis\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_DXA7MEP36BHC5XX7X27TEV97N9", "url": "https://statorigin.org/stat/stat_DXA7MEP36BHC5XX7X27TEV97N9", "indicator": { "slug": "ctgov-rnacv-trial-starts", "name": "Cardiometabolic RNA and next-generation lipid drug trial starts", "definition": "Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 12, "value_text": "12 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":12,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_5HJP6Q3PPPCH1GVM3C5B2KXM7B", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2024). ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_DXA7MEP36BHC5XX7X27TEV97N9", "bibtex": "@misc{clinicaltrialsgo2024ctgovev97n9,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_DXA7MEP36BHC5XX7X27TEV97N9},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran\\%20OR\\%20olpasiran\\%20OR\\%20lepodisiran\\%20OR\\%20zerlasiran\\%20OR\\%20pelacarsen\\%20OR\\%20muvalaplin\\%20OR\\%20zilebesiran\\%20OR\\%20plozasiran\\%20OR\\%20zodasiran\\%20OR\\%20solbinsiran\\%20OR\\%20olezarsen\\%20OR\\%20volanesorsen\\%20OR\\%20SLN360\\%20OR\\%20ARO-APOC3\\%20OR\\%20ARO-ANG3\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20lerodalcibep\\%20OR\\%20enlicitide\\%20OR\\%20MK-0616\\%20OR\\%20obicetrapib\\%20OR\\%20AZD0780\\%20OR\\%20vutrisiran\\%20OR\\%20patisiran\\%20OR\\%20eplontersen\\%20OR\\%20nucresiran\\%20OR\\%20TQJ230\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2024-01-01\\%2C2024-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_9RD6BQA3VYWGY3F7GHM34TT2AG", "url": "https://statorigin.org/stat/stat_9RD6BQA3VYWGY3F7GHM34TT2AG", "indicator": { "slug": "ctgov-rnacv-trial-starts", "name": "Cardiometabolic RNA and next-generation lipid drug trial starts", "definition": "Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 35, "value_text": "35 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China.", "quote": "{\"totalCount\":35,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_JMNG12BQ0RCA95401WQ6DE2RAD", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_9RD6BQA3VYWGY3F7GHM34TT2AG", "bibtex": "@misc{clinicaltrialsgo2026ctgov4tt2ag,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_9RD6BQA3VYWGY3F7GHM34TT2AG},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran\\%20OR\\%20olpasiran\\%20OR\\%20lepodisiran\\%20OR\\%20zerlasiran\\%20OR\\%20pelacarsen\\%20OR\\%20muvalaplin\\%20OR\\%20zilebesiran\\%20OR\\%20plozasiran\\%20OR\\%20zodasiran\\%20OR\\%20solbinsiran\\%20OR\\%20olezarsen\\%20OR\\%20volanesorsen\\%20OR\\%20SLN360\\%20OR\\%20ARO-APOC3\\%20OR\\%20ARO-ANG3\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20lerodalcibep\\%20OR\\%20enlicitide\\%20OR\\%20MK-0616\\%20OR\\%20obicetrapib\\%20OR\\%20AZD0780\\%20OR\\%20vutrisiran\\%20OR\\%20patisiran\\%20OR\\%20eplontersen\\%20OR\\%20nucresiran\\%20OR\\%20TQJ230\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_7E2NE2FQTHP6HBKB868K18N200", "url": "https://statorigin.org/stat/stat_7E2NE2FQTHP6HBKB868K18N200", "indicator": { "slug": "ctgov-rnacv-trial-starts", "name": "Cardiometabolic RNA and next-generation lipid drug trial starts", "definition": "Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 3, "value_text": "3 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":3,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_R7KBCBCG3V4H8D5R0QFEM12Y1X", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2022). ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_7E2NE2FQTHP6HBKB868K18N200", "bibtex": "@misc{clinicaltrialsgo2022ctgov18n200,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_7E2NE2FQTHP6HBKB868K18N200},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran\\%20OR\\%20olpasiran\\%20OR\\%20lepodisiran\\%20OR\\%20zerlasiran\\%20OR\\%20pelacarsen\\%20OR\\%20muvalaplin\\%20OR\\%20zilebesiran\\%20OR\\%20plozasiran\\%20OR\\%20zodasiran\\%20OR\\%20solbinsiran\\%20OR\\%20olezarsen\\%20OR\\%20volanesorsen\\%20OR\\%20SLN360\\%20OR\\%20ARO-APOC3\\%20OR\\%20ARO-ANG3\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20lerodalcibep\\%20OR\\%20enlicitide\\%20OR\\%20MK-0616\\%20OR\\%20obicetrapib\\%20OR\\%20AZD0780\\%20OR\\%20vutrisiran\\%20OR\\%20patisiran\\%20OR\\%20eplontersen\\%20OR\\%20nucresiran\\%20OR\\%20TQJ230\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2022-01-01\\%2C2022-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_SFX5ZQ1JQRJ0X61TEVC5RP6VBP", "url": "https://statorigin.org/stat/stat_SFX5ZQ1JQRJ0X61TEVC5RP6VBP", "indicator": { "slug": "ctgov-rnacv-trial-starts", "name": "Cardiometabolic RNA and next-generation lipid drug trial starts", "definition": "Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 25, "value_text": "25 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":25,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_D4VHJV1H4V2691H1SS9116AA3A", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2022). ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_SFX5ZQ1JQRJ0X61TEVC5RP6VBP", "bibtex": "@misc{clinicaltrialsgo2022ctgovrp6vbp,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_SFX5ZQ1JQRJ0X61TEVC5RP6VBP},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran\\%20OR\\%20olpasiran\\%20OR\\%20lepodisiran\\%20OR\\%20zerlasiran\\%20OR\\%20pelacarsen\\%20OR\\%20muvalaplin\\%20OR\\%20zilebesiran\\%20OR\\%20plozasiran\\%20OR\\%20zodasiran\\%20OR\\%20solbinsiran\\%20OR\\%20olezarsen\\%20OR\\%20volanesorsen\\%20OR\\%20SLN360\\%20OR\\%20ARO-APOC3\\%20OR\\%20ARO-ANG3\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20lerodalcibep\\%20OR\\%20enlicitide\\%20OR\\%20MK-0616\\%20OR\\%20obicetrapib\\%20OR\\%20AZD0780\\%20OR\\%20vutrisiran\\%20OR\\%20patisiran\\%20OR\\%20eplontersen\\%20OR\\%20nucresiran\\%20OR\\%20TQJ230\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2022-01-01\\%2C2022-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_Y61RAHK906SSHRJPEJEQ5K2AEA", "url": "https://statorigin.org/stat/stat_Y61RAHK906SSHRJPEJEQ5K2AEA", "indicator": { "slug": "ctgov-rnacv-trial-starts", "name": "Cardiometabolic RNA and next-generation lipid drug trial starts", "definition": "Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 30, "value_text": "30 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country.", "quote": "{\"totalCount\":30,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_T6P2GAM7HBD2DMYFVSJAQA7VAZ", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2025). ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_Y61RAHK906SSHRJPEJEQ5K2AEA", "bibtex": "@misc{clinicaltrialsgo2025ctgov5k2aea,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_Y61RAHK906SSHRJPEJEQ5K2AEA},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran\\%20OR\\%20olpasiran\\%20OR\\%20lepodisiran\\%20OR\\%20zerlasiran\\%20OR\\%20pelacarsen\\%20OR\\%20muvalaplin\\%20OR\\%20zilebesiran\\%20OR\\%20plozasiran\\%20OR\\%20zodasiran\\%20OR\\%20solbinsiran\\%20OR\\%20olezarsen\\%20OR\\%20volanesorsen\\%20OR\\%20SLN360\\%20OR\\%20ARO-APOC3\\%20OR\\%20ARO-ANG3\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20lerodalcibep\\%20OR\\%20enlicitide\\%20OR\\%20MK-0616\\%20OR\\%20obicetrapib\\%20OR\\%20AZD0780\\%20OR\\%20vutrisiran\\%20OR\\%20patisiran\\%20OR\\%20eplontersen\\%20OR\\%20nucresiran\\%20OR\\%20TQJ230\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2025-01-01\\%2C2025-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_99AG2PJCARV0FD70QMYGW2Y93M", "url": "https://statorigin.org/stat/stat_99AG2PJCARV0FD70QMYGW2Y93M", "indicator": { "slug": "ctgov-rnacv-trial-starts", "name": "Cardiometabolic RNA and next-generation lipid drug trial starts", "definition": "Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 32, "value_text": "32 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country.", "quote": "{\"totalCount\":32,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_J98AAJBJ974B8NDER10MATF96H", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2022). ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_99AG2PJCARV0FD70QMYGW2Y93M", "bibtex": "@misc{clinicaltrialsgo2022ctgovw2y93m,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_99AG2PJCARV0FD70QMYGW2Y93M},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran\\%20OR\\%20olpasiran\\%20OR\\%20lepodisiran\\%20OR\\%20zerlasiran\\%20OR\\%20pelacarsen\\%20OR\\%20muvalaplin\\%20OR\\%20zilebesiran\\%20OR\\%20plozasiran\\%20OR\\%20zodasiran\\%20OR\\%20solbinsiran\\%20OR\\%20olezarsen\\%20OR\\%20volanesorsen\\%20OR\\%20SLN360\\%20OR\\%20ARO-APOC3\\%20OR\\%20ARO-ANG3\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20lerodalcibep\\%20OR\\%20enlicitide\\%20OR\\%20MK-0616\\%20OR\\%20obicetrapib\\%20OR\\%20AZD0780\\%20OR\\%20vutrisiran\\%20OR\\%20patisiran\\%20OR\\%20eplontersen\\%20OR\\%20nucresiran\\%20OR\\%20TQJ230\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2022-01-01\\%2C2022-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_CMWG8GKCKJJYRABZZMBH1YP0EG", "url": "https://statorigin.org/stat/stat_CMWG8GKCKJJYRABZZMBH1YP0EG", "indicator": { "slug": "ctgov-rnacv-trial-starts", "name": "Cardiometabolic RNA and next-generation lipid drug trial starts", "definition": "Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2020-01-01", "end": "2020-12-31", "type": "year" }, "value": 0, "value_text": "0 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":0,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_J4HE53H1FK1VG20BGGX062BRPP", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2020). ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_CMWG8GKCKJJYRABZZMBH1YP0EG", "bibtex": "@misc{clinicaltrialsgo2020ctgov1yp0eg,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China},\n year = {2020},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_CMWG8GKCKJJYRABZZMBH1YP0EG},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran\\%20OR\\%20olpasiran\\%20OR\\%20lepodisiran\\%20OR\\%20zerlasiran\\%20OR\\%20pelacarsen\\%20OR\\%20muvalaplin\\%20OR\\%20zilebesiran\\%20OR\\%20plozasiran\\%20OR\\%20zodasiran\\%20OR\\%20solbinsiran\\%20OR\\%20olezarsen\\%20OR\\%20volanesorsen\\%20OR\\%20SLN360\\%20OR\\%20ARO-APOC3\\%20OR\\%20ARO-ANG3\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20lerodalcibep\\%20OR\\%20enlicitide\\%20OR\\%20MK-0616\\%20OR\\%20obicetrapib\\%20OR\\%20AZD0780\\%20OR\\%20vutrisiran\\%20OR\\%20patisiran\\%20OR\\%20eplontersen\\%20OR\\%20nucresiran\\%20OR\\%20TQJ230\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2020-01-01\\%2C2020-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_6KNQ3CT42K9RGS1DWN3FXWEKVM", "url": "https://statorigin.org/stat/stat_6KNQ3CT42K9RGS1DWN3FXWEKVM", "indicator": { "slug": "ctgov-rnacv-trial-starts", "name": "Cardiometabolic RNA and next-generation lipid drug trial starts", "definition": "Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 90, "value_text": "90 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States.", "quote": "{\"totalCount\":90,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_DQ358H70NGYH3DDDBXB1ZD0PKW", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_6KNQ3CT42K9RGS1DWN3FXWEKVM", "bibtex": "@misc{clinicaltrialsgo2026ctgovxwekvm,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_6KNQ3CT42K9RGS1DWN3FXWEKVM},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran\\%20OR\\%20olpasiran\\%20OR\\%20lepodisiran\\%20OR\\%20zerlasiran\\%20OR\\%20pelacarsen\\%20OR\\%20muvalaplin\\%20OR\\%20zilebesiran\\%20OR\\%20plozasiran\\%20OR\\%20zodasiran\\%20OR\\%20solbinsiran\\%20OR\\%20olezarsen\\%20OR\\%20volanesorsen\\%20OR\\%20SLN360\\%20OR\\%20ARO-APOC3\\%20OR\\%20ARO-ANG3\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20lerodalcibep\\%20OR\\%20enlicitide\\%20OR\\%20MK-0616\\%20OR\\%20obicetrapib\\%20OR\\%20AZD0780\\%20OR\\%20vutrisiran\\%20OR\\%20patisiran\\%20OR\\%20eplontersen\\%20OR\\%20nucresiran\\%20OR\\%20TQJ230\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_13GMS7GSBDFZ7Q3G0MP0B4B0VW", "url": "https://statorigin.org/stat/stat_13GMS7GSBDFZ7Q3G0MP0B4B0VW", "indicator": { "slug": "ctgov-rnacv-trial-starts", "name": "Cardiometabolic RNA and next-generation lipid drug trial starts", "definition": "Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2026-09-27", "type": "range" }, "value": 128, "value_text": "128 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country.", "quote": "{\"totalCount\":128,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_AHXTV9HX7KTNQ5MX00BDHND9NG", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_13GMS7GSBDFZ7Q3G0MP0B4B0VW", "bibtex": "@misc{clinicaltrialsgo2026ctgovb4b0vw,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_13GMS7GSBDFZ7Q3G0MP0B4B0VW},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran\\%20OR\\%20olpasiran\\%20OR\\%20lepodisiran\\%20OR\\%20zerlasiran\\%20OR\\%20pelacarsen\\%20OR\\%20muvalaplin\\%20OR\\%20zilebesiran\\%20OR\\%20plozasiran\\%20OR\\%20zodasiran\\%20OR\\%20solbinsiran\\%20OR\\%20olezarsen\\%20OR\\%20volanesorsen\\%20OR\\%20SLN360\\%20OR\\%20ARO-APOC3\\%20OR\\%20ARO-ANG3\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20lerodalcibep\\%20OR\\%20enlicitide\\%20OR\\%20MK-0616\\%20OR\\%20obicetrapib\\%20OR\\%20AZD0780\\%20OR\\%20vutrisiran\\%20OR\\%20patisiran\\%20OR\\%20eplontersen\\%20OR\\%20nucresiran\\%20OR\\%20TQJ230\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2026-09-27\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_6N0GQJK7AV2GW4V68QAHRD11T9", "url": "https://statorigin.org/stat/stat_6N0GQJK7AV2GW4V68QAHRD11T9", "indicator": { "slug": "ctgov-rnacv-trial-starts", "name": "Cardiometabolic RNA and next-generation lipid drug trial starts", "definition": "Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2021-01-01", "end": "2021-12-31", "type": "year" }, "value": 28, "value_text": "28 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country.", "quote": "{\"totalCount\":28,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_2D40CW9EX6ZMYD4XWTZ7C6MWQ5", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2021). ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_6N0GQJK7AV2GW4V68QAHRD11T9", "bibtex": "@misc{clinicaltrialsgo2021ctgovrd11t9,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country},\n year = {2021},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_6N0GQJK7AV2GW4V68QAHRD11T9},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran\\%20OR\\%20olpasiran\\%20OR\\%20lepodisiran\\%20OR\\%20zerlasiran\\%20OR\\%20pelacarsen\\%20OR\\%20muvalaplin\\%20OR\\%20zilebesiran\\%20OR\\%20plozasiran\\%20OR\\%20zodasiran\\%20OR\\%20solbinsiran\\%20OR\\%20olezarsen\\%20OR\\%20volanesorsen\\%20OR\\%20SLN360\\%20OR\\%20ARO-APOC3\\%20OR\\%20ARO-ANG3\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20lerodalcibep\\%20OR\\%20enlicitide\\%20OR\\%20MK-0616\\%20OR\\%20obicetrapib\\%20OR\\%20AZD0780\\%20OR\\%20vutrisiran\\%20OR\\%20patisiran\\%20OR\\%20eplontersen\\%20OR\\%20nucresiran\\%20OR\\%20TQJ230\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2021-01-01\\%2C2021-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_ERS3GMY4281T5QDEK67YAVGSGQ", "url": "https://statorigin.org/stat/stat_ERS3GMY4281T5QDEK67YAVGSGQ", "indicator": { "slug": "ctgov-rnacv-trial-starts", "name": "Cardiometabolic RNA and next-generation lipid drug trial starts", "definition": "Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 22, "value_text": "22 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country.", "quote": "{\"totalCount\":22,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_CPPK0PD8Z3X412Q82DPAC337Y8", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2023). ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_ERS3GMY4281T5QDEK67YAVGSGQ", "bibtex": "@misc{clinicaltrialsgo2023ctgovavgsgq,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_ERS3GMY4281T5QDEK67YAVGSGQ},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran\\%20OR\\%20olpasiran\\%20OR\\%20lepodisiran\\%20OR\\%20zerlasiran\\%20OR\\%20pelacarsen\\%20OR\\%20muvalaplin\\%20OR\\%20zilebesiran\\%20OR\\%20plozasiran\\%20OR\\%20zodasiran\\%20OR\\%20solbinsiran\\%20OR\\%20olezarsen\\%20OR\\%20volanesorsen\\%20OR\\%20SLN360\\%20OR\\%20ARO-APOC3\\%20OR\\%20ARO-ANG3\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20lerodalcibep\\%20OR\\%20enlicitide\\%20OR\\%20MK-0616\\%20OR\\%20obicetrapib\\%20OR\\%20AZD0780\\%20OR\\%20vutrisiran\\%20OR\\%20patisiran\\%20OR\\%20eplontersen\\%20OR\\%20nucresiran\\%20OR\\%20TQJ230\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2023-12-31\\%5D\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_VT17FMWWR3JND54XBA480ZQAXS", "url": "https://statorigin.org/stat/stat_VT17FMWWR3JND54XBA480ZQAXS", "indicator": { "slug": "ctgov-rnacv-trial-starts", "name": "Cardiometabolic RNA and next-generation lipid drug trial starts", "definition": "Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 35, "value_text": "35 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":35,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_0VQH2PG3JF0KTZAA19BDRHB1JT", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2024). ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_VT17FMWWR3JND54XBA480ZQAXS", "bibtex": "@misc{clinicaltrialsgo2024ctgov0zqaxs,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_VT17FMWWR3JND54XBA480ZQAXS},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran\\%20OR\\%20olpasiran\\%20OR\\%20lepodisiran\\%20OR\\%20zerlasiran\\%20OR\\%20pelacarsen\\%20OR\\%20muvalaplin\\%20OR\\%20zilebesiran\\%20OR\\%20plozasiran\\%20OR\\%20zodasiran\\%20OR\\%20solbinsiran\\%20OR\\%20olezarsen\\%20OR\\%20volanesorsen\\%20OR\\%20SLN360\\%20OR\\%20ARO-APOC3\\%20OR\\%20ARO-ANG3\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20lerodalcibep\\%20OR\\%20enlicitide\\%20OR\\%20MK-0616\\%20OR\\%20obicetrapib\\%20OR\\%20AZD0780\\%20OR\\%20vutrisiran\\%20OR\\%20patisiran\\%20OR\\%20eplontersen\\%20OR\\%20nucresiran\\%20OR\\%20TQJ230\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2024-01-01\\%2C2024-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_JGYCQSDRT5S1PVY4SD672ACDD6", "url": "https://statorigin.org/stat/stat_JGYCQSDRT5S1PVY4SD672ACDD6", "indicator": { "slug": "ctgov-rnacv-trial-starts", "name": "Cardiometabolic RNA and next-generation lipid drug trial starts", "definition": "Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 26, "value_text": "26 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":26,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_NJ714Y79E9GCGKSXTQHREYXQQA", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2025). ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_JGYCQSDRT5S1PVY4SD672ACDD6", "bibtex": "@misc{clinicaltrialsgo2025ctgov2acdd6,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_JGYCQSDRT5S1PVY4SD672ACDD6},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran\\%20OR\\%20olpasiran\\%20OR\\%20lepodisiran\\%20OR\\%20zerlasiran\\%20OR\\%20pelacarsen\\%20OR\\%20muvalaplin\\%20OR\\%20zilebesiran\\%20OR\\%20plozasiran\\%20OR\\%20zodasiran\\%20OR\\%20solbinsiran\\%20OR\\%20olezarsen\\%20OR\\%20volanesorsen\\%20OR\\%20SLN360\\%20OR\\%20ARO-APOC3\\%20OR\\%20ARO-ANG3\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20lerodalcibep\\%20OR\\%20enlicitide\\%20OR\\%20MK-0616\\%20OR\\%20obicetrapib\\%20OR\\%20AZD0780\\%20OR\\%20vutrisiran\\%20OR\\%20patisiran\\%20OR\\%20eplontersen\\%20OR\\%20nucresiran\\%20OR\\%20TQJ230\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2025-01-01\\%2C2025-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_SECQ1AFKPHMNRMRQ1X2PED6BBK", "url": "https://statorigin.org/stat/stat_SECQ1AFKPHMNRMRQ1X2PED6BBK", "indicator": { "slug": "ctgov-rnacv-trial-starts", "name": "Cardiometabolic RNA and next-generation lipid drug trial starts", "definition": "Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 12, "value_text": "12 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China.", "quote": "{\"totalCount\":12,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_ZV5AYMQ50HA0DWEFWT62H6279H", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2025). ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_SECQ1AFKPHMNRMRQ1X2PED6BBK", "bibtex": "@misc{clinicaltrialsgo2025ctgoved6bbk,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_SECQ1AFKPHMNRMRQ1X2PED6BBK},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran\\%20OR\\%20olpasiran\\%20OR\\%20lepodisiran\\%20OR\\%20zerlasiran\\%20OR\\%20pelacarsen\\%20OR\\%20muvalaplin\\%20OR\\%20zilebesiran\\%20OR\\%20plozasiran\\%20OR\\%20zodasiran\\%20OR\\%20solbinsiran\\%20OR\\%20olezarsen\\%20OR\\%20volanesorsen\\%20OR\\%20SLN360\\%20OR\\%20ARO-APOC3\\%20OR\\%20ARO-ANG3\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20lerodalcibep\\%20OR\\%20enlicitide\\%20OR\\%20MK-0616\\%20OR\\%20obicetrapib\\%20OR\\%20AZD0780\\%20OR\\%20vutrisiran\\%20OR\\%20patisiran\\%20OR\\%20eplontersen\\%20OR\\%20nucresiran\\%20OR\\%20TQJ230\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2025-01-01\\%2C2025-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" }, { "id": "stat_M1BXPHDNAD1BDA3P9JZVC8Y0RF", "url": "https://statorigin.org/stat/stat_M1BXPHDNAD1BDA3P9JZVC8Y0RF", "indicator": { "slug": "ctgov-rnacv-trial-starts", "name": "Cardiometabolic RNA and next-generation lipid drug trial starts", "definition": "Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 13, "value_text": "13 studies", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "ClinicalTrials.gov (U.S. National Library of Medicine)", "org_short_name": "ClinicalTrials.gov", "org_url": "https://clinicaltrials.gov", "org_tier": 1, "document_title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States", "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId", "document_type": "dataset", "locator": "totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States.", "quote": "{\"totalCount\":13,\"studies\":[", "published_date": null, "accessed_at": "2026-09-27", "license": "public-domain", "url_status": "ok", "self_reported": false }, "verification": "verified", "verified_by": "pipeline:ctgov-api-totalcount-verified", "verified_at": "2026-09-27T12:00:00.000Z", "confidence": 0.95, "is_secondhand": false, "supersedes": "stat_V8J2JASS5E7F72BG4HAQVHE4Q1", "superseded_by": null, "is_current": true, "citation": { "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2023). ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_M1BXPHDNAD1BDA3P9JZVC8Y0RF", "bibtex": "@misc{clinicaltrialsgo2023ctgovc8y0rf,\n author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n title = {ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_M1BXPHDNAD1BDA3P9JZVC8Y0RF},\n note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran\\%20OR\\%20olpasiran\\%20OR\\%20lepodisiran\\%20OR\\%20zerlasiran\\%20OR\\%20pelacarsen\\%20OR\\%20muvalaplin\\%20OR\\%20zilebesiran\\%20OR\\%20plozasiran\\%20OR\\%20zodasiran\\%20OR\\%20solbinsiran\\%20OR\\%20olezarsen\\%20OR\\%20volanesorsen\\%20OR\\%20SLN360\\%20OR\\%20ARO-APOC3\\%20OR\\%20ARO-ANG3\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20lerodalcibep\\%20OR\\%20enlicitide\\%20OR\\%20MK-0616\\%20OR\\%20obicetrapib\\%20OR\\%20AZD0780\\%20OR\\%20vutrisiran\\%20OR\\%20patisiran\\%20OR\\%20eplontersen\\%20OR\\%20nucresiran\\%20OR\\%20TQJ230\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2023-01-01\\%2C2023-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}" }, "updated_at": "2026-09-27T01:11:36.992Z" } ] }, "meta": { "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.", "license": "https://creativecommons.org/licenses/by/4.0/", "docs": "https://statorigin.org/docs/api", "total": 100, "note": "Statistics are capped at 100 per request. Use /statistics?source_org=clinicaltrials-gov with a cursor to page through everything." } }